<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003242" GROUP_ID="STROKE" ID="796000121414005626" MERGED_FROM="" MODIFIED="2011-03-07 13:15:39 +0100" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2011-03-07 13:15:39 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE>Anticoagulants versus antiplatelet agents for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2011-03-07 13:15:39 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="16436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Eivind</FIRST_NAME><LAST_NAME>Berge</LAST_NAME><EMAIL_1>eivind.berge@medisin.uio.no</EMAIL_1><ADDRESS><DEPARTMENT>Department of Cardiology</DEPARTMENT><ORGANISATION>Oslo University Hospital Ullevål</ORGANISATION><CITY>Oslo</CITY><ZIP>NO-0407</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 22 11 91 01</PHONE_1><FAX_1>+47 22 11 82 80</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-03-07 13:15:39 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="16436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Eivind</FIRST_NAME><LAST_NAME>Berge</LAST_NAME><EMAIL_1>eivind.berge@medisin.uio.no</EMAIL_1><ADDRESS><DEPARTMENT>Department of Cardiology</DEPARTMENT><ORGANISATION>Oslo University Hospital Ullevål</ORGANISATION><CITY>Oslo</CITY><ZIP>NO-0407</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 22 11 91 01</PHONE_1><FAX_1>+47 22 11 82 80</FAX_1></ADDRESS></PERSON><PERSON ID="8089" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>AG</MIDDLE_INITIALS><LAST_NAME>Sandercock</LAST_NAME><EMAIL_1>peter.sandercock@ed.ac.uk</EMAIL_1><URL>http://www.dcn.ed.ac.uk/csrg/</URL><ADDRESS><DEPARTMENT>Division of Clinical Neurosciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>Neurosciences Trials Unit, Bramwell Dott Building</ADDRESS_1><ADDRESS_2>Western General Hospital, Crewe Road</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH4 2XU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 537 2927</PHONE_1><FAX_1>+44 131 332 5150</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-16 15:15:00 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="27" MONTH="6" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2001"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-07 12:12:33 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-03-07 12:12:33 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="7" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Link to feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-03-07 12:12:06 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-03-07 12:12:06 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="8" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-08 09:53:57 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="16" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Edinburgh</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Norwegian Research Council</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-16 15:50:58 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-07-16 15:38:55 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-07-16 15:15:42 +0100" MODIFIED_BY="Hazel Fraser">Anticoagulants versus antiplatelet agents for acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-07-16 15:38:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>Treatment with anticoagulants offers no net advantages over antiplatelet agents in patients with acute ischaemic stroke. Ischaemic stroke is caused by a blood-clot blocking the blood supply to an area of the brain. Blood-thinning drugs, such as anticoagulants and antiplatelet agents, can potentially prevent arteries from being blocked, or prevent them re-blocking. They can also prevent clots forming in the deep veins in the leg, which can break off and travel to the lungs. However, such drugs can also cause bleeding complications, which might offset any benefits. Antiplatelet agents (mainly aspirin) are associated with long-term benefits and have become standard treatment for acute ischaemic stroke. This review aimed to test whether any anticoagulant regimen offers net advantages over antiplatelet agents, overall, or in specific categories of patients. There was no evidence that anticoagulants are superior to antiplatelet agents (in fact, anticoagulants caused a small increase in the number of deaths at long-term follow-up). However, the combination of low-dose anticoagulant and aspirin seemed to offer benefits over aspirin alone, and the combination should be investigated further.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-16 15:38:43 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND>
<P>Antiplatelet agents produce a small, but worthwhile benefit in long-term functional outcome and survival, and have become standard treatment for acute ischaemic stroke. Anticoagulants are often used as an alternative treatment, despite evidence that they are ineffective in producing long-term benefits. We wanted to review trials which have directly compared anticoagulants and antiplatelet agents, to assess whether any anticoagulant regimen offers net advantages over antiplatelet agents, overall or in some particular category of patients (e.g. patients with atrial fibrillation).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-07-16 15:14:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess: (1) the effectiveness of anticoagulants compared with antiplatelet agents in acute ischaemic stroke, and (2) whether the addition of anticoagulants to antiplatelet agents offers any net advantage over antiplatelet agents alone.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-16 15:14:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register, the Cochrane Controlled Trials Register, the trials register held by the Antithrombotic Therapy Trialists' Collaboration, MEDLINE (1966 to 2000), and EMBASE (1980 to 2000). All searches were performed during April and May 2001.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Truly unconfounded, randomised-controlled trials comparing anticoagulants with antiplatelet agents, or anticoagulants and antiplatelet agents with antiplatelet agents alone, given within 14 days of onset of presumed or confirmed ischaemic stroke.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Both reviewers independently selected trials for inclusion in the review, assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-07-16 15:38:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>A total of 16,558 patients from four trials contributed to the analyses. The methodological quality was high in all four trials. The anticoagulants tested were unfractionated heparin (UFH) and low molecular-weight heparin. Aspirin was used as control in all trials. Overall, there was no evidence that anticoagulants were superior to aspirin in reducing 'death or dependency' at long-term follow-up (odds ratio (OR) 1.07, 95% confidence interval (CI) 0.98 to 1.15). Compared with aspirin, anticoagulants were associated with a small but significant increase in the number of deaths at the end of follow-up (OR 1.10, 95% CI 1.01 to 1.29), equivalent to 20 more deaths (95% CI 0 to 30) per 1000 patients treated; a significant increased risk of symptomatic intracranial haemorrhage (OR 2.35, 95% CI 1.49 to 3.46); and a non-significant increased risk of 'any recurrent stroke' during treatment (OR 1.20, 95% CI 0.99 to 1.46). These neutral or adverse effects outweighed a small, but significant effect on symptomatic deep vein thrombosis (OR 1.20, 95% CI 0.07 to 0.58), equivalent to 10 fewer (95% CI 0 to 30) DVTs by 14 days per 1000 patients treated with anticoagulants instead of aspirin. Subgroup analysis could not identify any type, dose, or route of administration of anticoagulants associated with net benefit, or any benefit in patients with atrial fibrillation. Overall, the combination of UFH and aspirin did not appear to be associated with a net advantage over aspirin alone. A subgroup analysis showed that, compared with aspirin, the combination of low-dose UFH and aspirin was associated with a marginally significant reduced risk of 'any recurrent stroke' (OR 0.75, 95% CI 0.56 to 1.03) and a marginally significant reduced risk of death at 14 days (OR 0.84, 95% CI 0.69 to 1.01), and with no clear adverse effect on death at end of follow-up (OR 0.98, 95% CI 0.85 to 1.12).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Anticoagulants offered no net advantages over antiplatelet agents in acute ischaemic stroke. The combination of low-dose UFH and aspirin appeared in a subgroup analysis to be associated with net benefits compared with aspirin alone, and this merits further research. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-16 15:50:58 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2008-07-16 15:50:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>There are over one million new strokes each year in the European Union and the USA (<LINK REF="REF-Bamford-1990" TYPE="REFERENCE">Bamford 1990</LINK>; <LINK REF="REF-Broderick-1989" TYPE="REFERENCE">Broderick 1989</LINK>; <LINK REF="REF-Homer-1987" TYPE="REFERENCE">Homer 1987</LINK>), of which eighty-five per cent are ischaemic (<LINK REF="REF-Bamford-1990" TYPE="REFERENCE">Bamford 1990</LINK>). It is estimated that there will be 8.5 million patients with acute ischaemic stroke in these countries over the next decade, and of these, about one and a half million will die within six months of stroke onset (<LINK REF="REF-Sandercock-1992" TYPE="REFERENCE">Sandercock 1992</LINK>). Of those who survive, about one third will depend on other people for help with their activities of daily living (<LINK REF="REF-IST-1997" TYPE="REFERENCE">IST 1997</LINK>).</P>
<P>Most ischaemic strokes are due to the thrombotic or embolic occlusion of a cerebral artery. Immediate antithrombotic treatment with anticoagulant or antiplatelet drugs may reduce the volume of the infarcted cerebral tissue, and thereby reduce the risk of neurological deficits, disability, or death. It may also reduce the risk of early recurrent ischaemic stroke and venous thromboembolism. However, antithrombotic agents can also increase the risk of intracranial or extracranial haemorrhage, which may offset any benefits.</P>
<P>The net effects of anticoagulants (<LINK REF="REF-Gubitz-2001a" TYPE="REFERENCE">Gubitz 2001a</LINK>) and antiplatelet agents (<LINK REF="REF-Gubitz-2001b" TYPE="REFERENCE">Gubitz 2001b</LINK>) versus control have been reported in other Cochrane systematic reviews. Antiplatelet agents (mainly aspirin) reduce the risk of early recurrent ischaemic stroke (by 7 per 1000 patients treated), with only a minimal increase in the risk of haemorrhage (2 per 1000), and produce a small, but worthwhile benefit in long-term outcome (13 more patients alive and independent per 1000 patients treated). Aspirin is inexpensive and easy to use and has now become 'standard' treatment for patients with acute ischaemic stroke. Anticoagulants may offer a more potent antithrombotic effect and produce an even greater effect on recurrent ischaemic stroke (9 per 1000), but this is offset by a similar-sized increase in the risk of symptomatic intracranial haemorrhage (9 per 1000), which cancels out any long-term benefits.</P>
<P>Given the potential for world-wide use of antithrombotic treatment in acute stroke, there is a need to identify whether any anticoagulant regimen offers net advantages over antiplatelet agents, overall, or in some particular category of patients (e.g. patients with atrial fibrillation). Indirect comparisons are likely to be biased (due to differences between the groups other than the agents being tested), and so direct comparisons are needed before valid conclusions can be drawn. A systematic overview of randomised, unconfounded trials is also needed to identify whether the addition of anticoagulants to antiplatelet agents offers any advantage over antiplatelet agents alone.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-07-16 15:15:56 +0100" MODIFIED_BY="Hazel Fraser">
<P>(1) To assess the effectiveness and safety of anticoagulants compared with antiplatelet agents, given within 14 days of onset of acute ischaemic stroke.<BR/>(2) To assess whether the addition of anticoagulants to antiplatelet agents offers any net advantage over antiplatelet agents alone.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-16 15:46:11 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-07-16 15:16:36 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>We sought all unconfounded, truly randomised-controlled trials in which treatment with anticoagulants was directly compared with antiplatelet agents in patients with presumed or confirmed acute ischaemic stroke. Trials in which allocation was not truly random (e.g. allocation by alternation, date of birth, hospital number, day of the week) or where allocation is not adequately concealed (e.g. open random number list) were not included, since foreknowledge of treatment allocation can lead to biased treatment allocation, which may cause overestimation of the treatment effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). If it was unclear whether the method of randomisation provided adequate concealment of allocation, the trial was included. Randomised controlled trials in which anticoagulants plus antiplatelet agents were compared with antiplatelet agents alone were included, as this represents an unconfounded comparison.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All trials which randomised patients within 14 days of onset of acute ischaemic stroke were included. Trials in which the pathological type of stroke was not confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) before entry, were included, as the majority of such strokes are ischaemic, at least in Caucasians (<LINK REF="REF-Bamford-1990" TYPE="REFERENCE">Bamford 1990</LINK>). We excluded trials in patients with transient ischaemic attacks only.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Anticoagulants are broadly defined as those which act on the coagulation cascade to exert an anticoagulant effect, excluding thrombolytic agents (e.g. streptokinase agents) or defibrinogenating agents (e.g. ancrod). The use of thrombolytic agents in acute ischaemic stroke is the subject of a separate Cochrane review (<LINK REF="REF-Wardlaw-2001" TYPE="REFERENCE">Wardlaw 2001</LINK>), as is the use of fibrinogen depleting agents (<LINK REF="REF-Liu-2001" TYPE="REFERENCE">Liu 2001</LINK>). The following anticoagulants were included in this review: subcutaneous and intravenous standard unfractionated heparin (UFH), low molecular-weight heparins (LMWHs), subcutaneous and intravenous heparinoids, oral anticoagulants (e.g. warfarin) and specific thrombin inhibitors (e.g. lepirudin).</P>
<P>Antiplatelet agents are broadly defined as any agents (alone, or in combination with other antiplatelet agents) whose principal effects are to inhibit platelet adhesion and aggregation. These include: cyclo-oxygenase inhibitors (e.g. acetylsalicylic acid), thienopyridine derivatives (e.g. ticlopidine), phosphodiesterase inhibitors (e.g. dipyridamole), thromboxane A2 antagonists, and agents with direct effects on platelet membrane receptors such as GPIIb/IIIa receptor blockers (e.g. abciximab) and fibrinogen antagonists (e.g. defibrotide). Agents with some antiplatelet activity but whose principal action is unclear were not included (e.g. piracetam, prostacyclin, oxpentifylline). Some of these agents are evaluated in other Cochrane systematic reviews (<LINK REF="REF-Bath-2001a" TYPE="REFERENCE">Bath 2001a</LINK>; <LINK REF="REF-Bath-2001b" TYPE="REFERENCE">Bath 2001b</LINK>; <LINK REF="REF-Ricci-2001" TYPE="REFERENCE">Ricci 2001</LINK>).</P>
<P>The review includes trials with a variety of primary objectives including: acute treatment of the cerebral infarction, prevention of thrombus progression or recurrence, and prevention of venous thromboembolism.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-16 15:16:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>For each trial, the number of patients originally allocated at random to each treatment group was identified. In both groups, outcome information was sought regarding the number of patients:<BR/>(1) who were either dead or dependent at end of follow-up (minimum one month). Dependency was defined as dependency on other people for activities of daily living, or as a modified Rankin Scale score of 3 to 5 inclusive. The minimum interval of one month was used to allow time for recovery from the initial stroke;<BR/>(2) who died from any cause during the scheduled follow-up period (minimum one month);<BR/>(3) who died from any cause during the scheduled treatment period;<BR/>(4) with objective evidence of deep vein thrombosis (DVT) during the scheduled treatment period, both symptomatic DVT, and total (asymptomatic plus symptomatic) DVT, detected by systematic use of imaging techniques such as iodine 125 fibrinogen scanning (1-125 scan), ultrasound of the leg, plethysmography, or X-ray contrast venography. These methods therefore detected clinically silent DVT as well as confirming or refuting the diagnosis in patients with clinical features suggestive of DVT;<BR/>(5) with symptomatic pulmonary embolism (PE) diagnosed during the scheduled treatment period, or asymptomatic or symptomatic PE diagnosed at autopsy during the scheduled treatment period;<BR/>(6) with progression of symptoms ('progressive stroke'/neurological deterioration) during the scheduled treatment period;<BR/>(7) with recurrent stroke during the scheduled treatment period, either ischaemic (haemorrhage excluded by CT/MRI scanning or autopsy) or of unknown type (no CT/MRI or autopsy performed);<BR/>(8) with symptomatic intracranial haemorrhage during the scheduled treatment period, including symptomatic haemorrhagic transformation of the cerebral infarct, confirmed by CT/MRI scanning or autopsy;<BR/>(9) with any recurrent stroke (ischaemic/unknown or haemorrhagic, as previously defined) during the scheduled treatment period; and<BR/>(10) with any major extracranial haemorrhage during the scheduled treatment period. The definition of major haemorrhage was usually taken from the original article but if none was given it was defined as any fatal bleed, or bleeding severe enough to require transfusion, operation, or prolongation of hospital stay.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-16 15:23:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group Trials Register. We also searched the Cochrane Controlled Trials Register (Central/CCTR, <I>The Cochrane Library</I> Issue 3 2001) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), the trials register held by the Antithrombotic Therapy Trialists' Collaboration, MEDLINE (1966 to 2000) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and EMBASE (1980 to 2000) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). All searches were performed during April and May 2001. Titles, keywords and abstracts of the citations downloaded from the electronic searches were screened, and full copies of reports of potential trials were obtained for further assessment. Reference lists of articles were searched, and a comprehensive guide to pharmaceutical development in the field of stroke was consulted (<LINK REF="REF-MedStrategy-1995" TYPE="REFERENCE">MedStrategy 1995</LINK>).</P>
<P>Of the over 4000 reports of trials in the Cochrane Stroke Group Trials Register only 31 have been found through direct contact with pharmaceutical companies (November 2000), of which none were relevant for this review. Pharmaceutical companies were therefore not contacted to identify unpublished trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-16 15:46:11 +0100" MODIFIED_BY="Hazel Fraser">
<P>One reviewer (EB) screened the reference lists retrieved by the searches and identified potential trials for the review. From the list of candidate trials, the reviewers then independently selected the trials for the review according to the criteria outlined above. Both reviewers independently extracted and cross-checked data. Data were extracted from the publications onto data extraction forms by one reviewer, and then checked by the other. Disagreements were resolved by discussion between the two reviewers.</P>
<P>The methodological quality was assessed by recording details of randomisation method, blinding, whether intention-to-treat analyses were possible from the published data, and whether any patients were lost to follow-up. Data on the number of patients with each outcome or event, by allocated treatment group, irrespective of compliance, and whether or not the patient was subsequently deemed ineligible or otherwise excluded from treatment or follow-up, were sought to allow an "intention-to-treat" analysis. Data on the use of CT or MRI scanning prior to randomisation, the delay from stroke onset to trial entry, the type of patients included, and the type of anticoagulant regimen used were also sought. If any of the above data were not available in the publications, further information were sought by correspondence with the trialists.</P>
<P>Both proportional and absolute risk reductions were calculated for each outcome. Heterogeneity between trial results was tested using a standard chi-squared test. The results were reported as odds ratios, using the fixed-effects method (<LINK REF="REF-APT-1994" TYPE="REFERENCE">APT 1994</LINK>). The significance of any differences between odds ratios was calculated using a standard method (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). For some outcomes (e.g. DVT and symptomatic intracranial haemorrhage), intention-to-treat analyses were not possible because all patients did not have the relevant investigation performed to detect the event. In these analyses, the number of patients in each group who had the appropriate investigation was used as the denominator. Where indicated, absolute treatment effects (i.e. the number of events avoided for every 1000 patients treated) were calculated.</P>
<P>Trials of each type of anticoagulant (e.g. UFHs, LMWHs, heparinoids, oral anticoagulants, thrombin inhibitors) and antiplatelet agent were grouped together to assess whether there are any significant differences between the various classes of anticoagulants and antiplatelet agents. It should be noted that this is an indirect rather than a direct randomised comparison. We specified the following classification of anticoagulant dosing regimens:<BR/>(1) UFH high dose, i.e. a dose intended to be sufficient to have effects on the arterial circulation, defined as 20,000 IU or more per day<BR/>(2) UFH low dose, i.e. a dose intended to be sufficient for the prevention of DVT and PE, defined as less than 20,000 IU per day<BR/>(3) LMWH high dose, defined as 150 IU or more per day<BR/>(4) LMWH low dose, defined as less than 150 IU per day</P>
<P>The following subgroup and sensitivity analyses were pre-specified for the major outcomes of the review.<BR/>
</P>
<UL>
<LI>Trials in which the method of randomisation ensured adequate concealment of treatment allocation</LI>
<LI>The type of anticoagulant agent used</LI>
<LI>Trials in which all patients had intracerebral haemorrhage excluded by CT or MR scanning prior to trial entry, since the risk from anticoagulation may be higher in patients with intracerebral haemorrhage.</LI>
<LI>The time from stroke onset to randomisation (i.e. &lt;48 hours or =/&gt;48 hours)</LI>
<LI>Trials in which the combination of antiplatelet agents and anticoagulants were compared with antiplatelet agents alone</LI>
<LI>Trials which evaluated different anticoagulant dosages ('high dose' versus 'low dose')</LI>
<LI>Trials in which the stroke was of suspected cardioembolic origin versus non-cardioembolic origin</LI>
</UL>
<P>Readers should make due allowance for the exploratory nature of these analyses.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-16 15:46:28 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-07-16 15:24:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>Four trials with a total of 21,448 patients were included, of which 16,558 patients contribute data to this review. IST 1997 included 19,435 patients, but 4,860 of the patients were randomised to avoid heparin and aspirin and so only 14,575 IST patients provide data for this review (88% of all patients in the review). Not all the trials contributed data to both comparisons, and so a total of 11,721 patients contributed data to the comparison of anticoagulants versus antiplatelet agents, and 9,720 patients contributed data to the comparison of anticoagulants plus antiplatelet agents versus antiplatelet agents alone. Also, not all of the trials provided data for every outcome of interest. Thus, the number of patients contributing data to the different analyses varied from 75 (analysis of "asymptomatic or symptomatic deep vein thrombosis") to 11,721 ("death at end of treatment period"). Summary details of the included trials are given in the 'Characteristics of Included Studies' section. Three other studies are on-going (see the 'Characteristics of Ongoing Studies' section), and eight were excluded for a variety of reasons (see the 'Characteristics of Excluded Studies' section).</P>
<P>All studies included a wide variety of patients with acute ischaemic stroke, although <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK> restricted entry to patients with lower limb paresis, and <LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK> restricted entry to patients with atrial fibrillation. Most patients were over 70 years old, and those with the very mildest (e.g. no motor symptoms) or most severe symptoms (e.g. coma) were generally excluded from all studies (<LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK> also excluded patients with significant midline shift on CT). All trials sought to include only patients with non-haemorrhagic strokes (confirmed by CT or, in <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK>, by lumbar puncture). In IST 29% of the patients were first scanned after randomisation, and subsequent CT showed that in 3% of the patients in IST the cerebrovascular event leading to randomisation was a cerebral haemorrhage. These patients are included in the analyses.</P>
<P>Two trials (<LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK> and <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>) used UFH, and two trials (<LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>) used LMWH. <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK> used two different heparin doses, classified in this review as 'high' and 'low' dose. All four trials used aspirin in the control group. <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> randomised patients to heparin, aspirin, both, or neither in a 2x3 factorial design. This allowed us to also compare the combination of UFH and aspirin with aspirin alone.</P>
<P>All trials included patients within 48 hours of stroke onset. The scheduled period of treatment was 10 days (<LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>) or 14 days (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> and <LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK>), and the follow-up period was 10 days (<LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK>), 3 months (<LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK>) or 6 months (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>). The measures of outcome were comparable in all four trials. The primary measure of outcome in the two largest trials (<LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>) was functional outcome at end of follow-up (6 months). 'Dependency' was defined as needing help from other people in activities of daily living in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> and <LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK>, and as a modified Rankin Scale score of 3 to 5 inclusive in <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>. The primary events in <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK> and <LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK> was asymptomatic or symptomatic DVT, and recurrent ischaemic stroke, respectively.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All trials were truly randomised-controlled and all reported adequate concealment of treatment allocation (note: for <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>, information about method of concealment is awaited). The trials using LMWH (<LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>) were double-blind, whereas <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK> and <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> were open. However, assessment of outcome at end of follow-up was effectively blinded in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, as outcome was assessed by a questionnaire or telephone interview by a person blinded to treatment allocation.</P>
<P>None of the trials reported significant imbalances in important baseline prognostic variables. <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK> excluded two of 1486 randomised patients from the analysis, and Prince 1981 excluded five of 40 patients randomised to antiplatelet therapy. Analysis was otherwise by intention-to-treat in all trials. Follow-up was complete or near complete in all four trials.<BR/> </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-16 15:46:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>Both main comparisons were made for outcomes for which there were collected appropriate data: anticoagulants versus antiplatelet agents (comparison 1), and anticoagulants plus antiplatelet agents versus antiplatelet agents alone (comparison 2). The analyses are shown in the order of the following outcomes, first for comparison 1, then for comparison 2.</P>
<SUBSECTION>
<HEADING LEVEL="3">Death or dependency at end of follow-up</HEADING>
<P>Data on 11,527 patients were available for the analysis of 'death or dependency' at end of follow-up. There was no evidence that anticoagulants, compared with aspirin, reduced the number of patients who were dead or dependent at end of follow-up (OR 1.07, 95% CI 0.99 to 1.15). There was no heterogeneity of effect between trials of UFH, LMWH, high or low dose, and there was no advantage of anticoagulants compared with antiplatelet agents in the subgroup of patients with atrial fibrillation (OR 1.10, 95% CI 0.90 to 1.35, data from <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> and <LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK> only). We also compared UFH plus aspirin with aspirin alone, using data from <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>, but there was no evidence of difference in effect overall (OR 1.00, 95% CI 0.92 to 1.09), or in patients with atrial fibrillation (OR 1.00, 95% CI 0.92 to 1.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Deaths by the end of follow-up</HEADING>
<P>Data on 11,567 patients were available for this analysis, which showed that, compared with aspirin, anticoagulants were associated with a small, but significant increase in the number of deaths by the end of follow-up (OR 1.10, 95% CI 1.01 to 1.21), equivalent to 20 (95% CI 0 to 30) more deaths per 1000 patients treated with anticoagulants. The result was attributed to the analysis of patients receiving high dose or low dose UFH in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>. The comparison of the combination of UFH and aspirin versus aspirin alone in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> showed that there was a non-significant trend towards a higher case fatality with high dose UFH plus aspirin versus aspirin alone (OR 1.11, 95% CI 0.97 to 1.27), but there was no difference when the high and low dose UFH groups were combined (OR 1.04, 95% CI 0.95 to 1.15). For patients with atrial fibrillation the results were similar, for this outcome as well as for all of the following outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Deaths during the treatment period</HEADING>
<P>There was no difference between anticoagulants and antiplatelet agents in the number of deaths by the end of the treatment period (OR 1.04, 95% CI 0.92 to 1.19). There was no evidence of heterogeneity, and no advantage of anticoagulants over antiplatelet agents in any of the pre-specified subgroup analyses. There was also no significant difference in case fatality between patients receiving UFH plus aspirin and patients receiving aspirin alone, although there was a non-significantly better outcome in patients receiving the combination of low dose UFH and aspirin (OR 0.84, 95% CI 0.69 to 1.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Deep vein thrombosis during the treatment period</HEADING>
<P>Only <LINK REF="STD-Pince-1981" TYPE="STUDY">Pince 1981</LINK> performed systematic tests to detect asymptomatic DVT, but found no significant difference between low dose UFH and aspirin in the prevention of asymptomatic or symptomatic DVT (OR 1.03, 95% 0.31 to 3.40). However, this trial is so small that it would have required an extreme result to show a significant result. <LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK> reported the number of symptomatic DVTs and found significantly fewer symptomatic DVTs during the treatment period among patients allocated to anticoagulants (OR 0.19, 95% CI 0.07 to 0.58), which corresponds to 10 fewer (95% CI 0 to 30 fewer) DVTs per 1000 patients treated with LMWH instead of aspirin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Symptomatic pulmonary embolism during the treatment period</HEADING>
<P>Compared with aspirin, anticoagulants were associated with non-significantly fewer symptomatic PEs (OR 0.85, 95% CI 0.55 to 1.32). The difference was larger in trials using high dose (OR 0.44, 95% CI 0.08 to 2.33) than low dose LMWH (OR 0.97, 95% CI 0.18 to 5.31), but the difference between the high and low dose was not significant (p=0.8). A similar dose-dependent pattern was observed when we compared UFH plus aspirin with aspirin alone in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>. Overall, there was a significant reduction in the number of symptomatic PE with the combination of UFH and aspirin (OR 0.58, 95% CI 0.34 to 1.00), equivalent to 5 fewer (0 to 10 fewer) PE per 1000 patients treated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Progression of symptoms during the treatment period</HEADING>
<P>Progression/neurological deterioration was only recorded in the trials of LMWH (<LINK REF="STD-HAEST-2000" TYPE="STUDY">HAEST 2000</LINK> and <LINK REF="STD-TAIST-2001" TYPE="STUDY">TAIST 2001</LINK>). There was no significant difference in the number of neurological deteriorations during treatment (OR 1.10, 95% 0.82 to 1.48).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Recurrent stroke of ischaemic or unknown type during the treatment period</HEADING>
<P>There was no evidence that anticoagulants, either UFH or LMWH, high dose or low dose, were superior to aspirin for the prevention of recurrent stroke during the first 10 to 14 days of treatment (overall OR 1.09, 95% CI 0.89 to 1.33). However, there was evidence of a beneficial effect of the combination of UFH and aspirin over aspirin alone (OR 0.76, 95% CI 0.59 to 0.96), equivalent to 10 fewer (95% CI 0 to 10 fewer) recurrent strokes per 1000 patients treated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Symptomatic intracranial haemorrhage during the treatment period</HEADING>
<P>Anticoagulants were associated with a significant increase in the risk of symptomatic intracranial haemorrhage (OR 2.27, 95% CI 1.49 to 3.46), equivalent to 10 more (95% CI 0 to 10 more) symptomatic intracranial haemorrhages per 1000 patients treated. The difference was greater in trials using high dose (OR 3.24, 95% CI 2.09 to 5.04) than low dose anticoagulants (OR 1.29, 95% CI 0.72 to 2.32), and the difference between the high- and low-dose was statistically significant (p=0.014). A similar dose-dependent pattern was observed when comparing UFH plus aspirin with aspirin alone in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>. Overall, there was a significant increase in the number of symptomatic intracranial haemorrhages with the combination of UFH and aspirin (OR 2.36, 95% CI 1.49 to 3.37), equivalent to 10 more (0 to 10 more) symptomatic intracranial haemorrhages per 1000 patients treated. For low dose UFH the increase in risk was not significant (OR 1.46, 95% CI 0.72 to 2.97)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Any recurrent stroke (ischaemic, unknown or haemorrhagic type) during the treatment period</HEADING>
<P>Compared with aspirin, anticoagulants were associated with a non-significant increase in the risk of recurrent stroke (OR 1.20, 95% CI 0.99 to 1.46), equivalent to 10 more (95% CI 0 to 10 more) recurrent strokes per 1000 patients treated. This was largely attributable to the patients receiving high dose UFH in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> (OR 1.38, 95% CI 1.05 to 1.82). The analysis of UFH plus aspirin versus aspirin alone revealed that, whereas there was a trend towards increased risk of recurrent stroke with high dose UFH (OR 1.22, 95% CI 0.92 to 1.62), there was a non-significantly reduced risk of recurrent stroke with low dose UFH (OR 0.75, 95% CI 0.56 to 1.03), equivalent to 10 fewer (95% CI 0 to 20 fewer) recurrent strokes per 1000 patients treated. The difference between high dose and low dose UFH was statistically significant (p=0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Major extracranial haemorrhage during the treatment period</HEADING>
<P>Anticoagulants were associated with a significant increase in the risk of major extracranial haemorrhage (OR 1.94, 95% CI 1.20 to 3.12), equivalent to 5 more (95% CI 0 to 10 more) major extracranial haemorrhages per 1000 patients treated. There was heterogeneity of effect between the trials, which was caused by patients receiving high dose UFH in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK> (OR 2.78, 95% CI 1.43 to 5.39). Again, a similar dose-dependent pattern was observed when comparing UFH plus aspirin with aspirin alone in <LINK REF="STD-IST-1997" TYPE="STUDY">IST 1997</LINK>. Overall, there was a significant increase in the number of major extracranial haemorrhages with the combination of UFH and aspirin (OR 3.79, 95% CI 2.39 to 6.01), equivalent to 10 more (95% CI 10 more to 20 more) major extracranial haemorrhages per 1000 patients treated. For low dose UFH the increase in risk was not statistically significant (OR 1.82, 95% CI 0.87 to 3.81). The difference between high dose and low dose UFH was statistically significant (p=0.002).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-16 15:43:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>There was no evidence from the trials performed to date that anticoagulants offer a net advantage over antiplatelet agents in patients with acute ischaemic stroke. On the contrary, there was evidence to suggest that anticoagulants were inferior to antiplatelet agents. Overall, anticoagulants were associated with a small but significant increase in the number of deaths at the end of follow-up, equivalent to 20 more deaths per 1000 patients treated with anticoagulants. This adverse effect can probably partly be attributed to the 10 extra symptomatic intracranial haemorrhages, and the 5 extra major extracranial haemorrhages per 1000 patients treated with anticoagulants.</P>
<P>The systematic review also did not identify any type, dose, or route of administration of anticoagulant drug associated with net benefits, which is consistent with another systematic review comparing LMWHs or heparinoids with UFH (<LINK REF="REF-Counsell-2001" TYPE="REFERENCE">Counsell 2001</LINK>). Neither did we demonstrate any benefit of anticoagulants in patients with atrial fibrillation. Another systematic review comparing anticoagulants with control also could not identify subgroups showing net benefit from anticoagulant treatment, including those with: presumed cardioembolic stroke, 'stroke in progression', vertebrobasilar territory stroke, or following thrombolysis for acute ischaemic stroke to prevent re-thrombosis (<LINK REF="REF-Gubitz-2001a" TYPE="REFERENCE">Gubitz 2001a</LINK>). Finally, the results were internally consistent across all the outcomes we studied.</P>
<P>These neutral or negative results were somewhat counterbalanced by a small, but significant effect of anticoagulants over aspirin in the prevention of symptomatic DVT, equivalent to 10 (95% CI 10 to 20) fewer DVTs per 1000 patients treated, and a small and non-significant effect on PE, equivalent to 5 (95% CI 0 to 10) fewer PE per 1000 patients treated. However, the overall incidence of symptomatic DVT and PE was low (1.1% and 0.7%, respectively), presumably reflecting that other routine measures for preventing venous thromboembolism (such as hydration, compression stockings, and early mobilisation) were effectively controlling this problem. Therefore, while the relative risk reduction may seem substantial, the absolute reduction in DVT and PE is relatively small, and, in our view, does not justify the routine use of anticoagulants for acute ischaemic stroke. There is also evidence to support the use of antiplatelet agents in DVT and PE prophylaxis in other categories of high-risk patients (<LINK REF="REF-APT-1994" TYPE="REFERENCE">APT 1994</LINK>, <LINK REF="REF-PEP-trial-2000" TYPE="REFERENCE">PEP trial 2000</LINK>).</P>
<P>High dose anticoagulants were associated with significantly more recurrent strokes (of ischaemic/unknown or haemorrhagic type), symptomatic intracranial haemorrhages, and major extracranial haemorrhages than low-dose heparin in indirect comparisons. The same pattern was also seen when UFH and aspirin given concurrently was compared with aspirin alone, and, overall the combination of UFH plus aspirin did not appear to be associated with a net advantage over aspirin alone. However, a subgroup analysis suggested promising benefits of low dose UFH plus aspirin over aspirin alone. Compared with aspirin alone, the combination of low-dose UFH and aspirin was associated with a marginally significant reduced risk of 'any recurrent stroke' and a marginally significant reduced risk of death at 14 days, and with no clear adverse effect on death at end of follow-up. It is plausible that the addition of low dose heparin to aspirin might confer benefits compared with aspirin alone, but a very large trial would be needed to confirm or refute such modest effects.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-07-16 15:27:17 +0100" MODIFIED_BY="Hazel Fraser">
<IMPLICATIONS_PRACTICE MODIFIED="2008-07-16 15:26:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is no evidence from this systematic review that anticoagulants are superior to antiplatelet agents for patients with acute ischaemic stroke. Instead, the review suggests that anticoagulants are associated with a small but significant increase in the number of deaths at the end of follow-up. The analysis performed could not identify any type, dose, or route of administration of anticoagulants associated with net benefit, and showed no benefits in patients with atrial fibrillation. In patients with acute ischaemic stroke, antiplatelet agents produce modest, but worthwhile benefits, and should therefore be the antithrombotic agents of first choice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-16 15:27:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>Data from this review show that the combination of low dose UFH and aspirin might be associated with net benefits over aspirin alone, and this might be worth testing in further large-scale randomised-controlled trials. At least three trials are on-going. This review has not provided clear evidence about the optimum antithrombotic regimen for the prevention of DVT and PE in acute stroke. Aspirin alone, low-dose heparin, the combination of the two, or the use of compression stockings are all alternatives, but a large randomised controlled trial with several thousands of patients would be required for such a trial to provide a reliable result.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Prof Philip Bath for providing unpublished data from the TAIST. We would also like to thank Hazel Fraser, Co-ordinator of the Cochrane Stroke Group, for providing updates of newly identified trials, and Brenda Thomas, the Trial Search Co-ordinator, for help with trial searching. Eivind Berge was supported by a grant from the Norwegian Research Council.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Peter Sandercock was the principal investigator of the International Stroke Trial and Eivind Berge was the trial co-ordinator of the Heparin in Acute Embolic Stroke Trial.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Eivind Berge wrote first draft of the protocol, redrafted it in the light of comments, did the searches and identified trials, extracted data and performed the analyses, and wrote the review.<BR/>Peter Sandercock commented on the protocol, independently selected studies for inclusion in the review, independently extracted data, and commented on the draft review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-16 16:03:57 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-07-16 16:02:27 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2008-07-16 16:00:59 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="MIX" ID="STD-HAEST-2000" MODIFIED="2008-07-16 16:00:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="HAEST 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-07-16 16:00:26 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berge E, Abdelnoor M, Nakstad PH, Sandset PM</AU>
<TI>Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>1205-1210</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:00:18 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-IST-1997" MODIFIED="2008-07-16 16:00:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="IST 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-07-16 16:00:35 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;97317545 England BACKGROUND: Only a few small trials have compared antithrombotic therapy (antiplatelet or anticoagulant agents) versus control in acute ischaemic stroke, and none has been large enough to provide reliable evidence on safety or efficacy. METHODS: The International Stroke Trial (IST) was a large, randomised, open trial of up to 14 days of antithrombotic therapy started as soon as possible after stroke onset. The aim was to provide reliable evidence on the safety and efficacy of aspirin and of subcutaneous heparin. Half the patients were allocated unfractionated heparin (5000 or 12,500 IU bd [twice daily]), and half were allocated &amp;quot;avoid heparin&amp;quot;; and, in a factorial design, half were allocated aspirin 300 mg daily and half &amp;quot;avoid aspirin&amp;quot;. The primary outcomes were death within 14 days and death or dependency at 6 months. 19,435 patients with suspected acute ischaemic stroke entering 467 hospitals in 36 countries were randomised within 48 hours of symptom onset. RESULTS: Among heparin-allocated patients, there were non-significantly fewer deaths within 14 days (876 [9.0%] heparin vs 905 [9.3%] no heparin), corresponding to 3 (SD 4) fewer deaths per 1000 patients. At 6 months the percentage dead or dependent was identical in both groups (62.9%). Patients allocated to heparin had significantly fewer recurrent ischaemic strokes within 14 days (2.9% vs 3.8%) but this was offset by a similar-sized increase in haemorrhagic strokes (1.2% vs 0.4%), so the difference in death or non-fatal recurrent stroke (11.7% vs 12.0%) was not significant. Heparin was associated with a significant excess of 9 (SD 1) transfused or fatal extracranial bleeds per 1000. Compared with 5000 IU bd heparin, 12,500 IU bd heparin was associated with significantly more transfused or fatal extracranial bleeds, more haemorrhagic strokes, and more deaths or non-fatal strokes within 14 days (12.6% vs 10.8%). Among aspirin-allocated patients there were non-significantly fewer deaths within 14 days (872 [9.0%] vs 909 [9.4%]), corresponding to 4 (SD 4) fewer deaths per 1000 patients. At 6 months there was a non-significant trend towards a smaller percentage of the aspirin group being dead or dependent (62.2% vs 63.5%, 2p = 0.07), a difference of 13 (SD 7) per 1000; after adjustment for baseline prognosis the benefit from aspirin was significant (14 [SD 6] per 1000, 2p = 0.03). Aspirin-allocated patients had significantly fewer recurrent ischaemic strokes within 14 days (2.8% vs 3.9%) with no significant excess of haemorrhagic strokes (0.9% vs 0.8%), so the reduction in death or non-fatal recurrent stroke with aspirin (11.3% vs 12.4%) was significant. Aspirin was associated with a significant excess of 5 (SD 1) transfused or fatal extracranial bleeds per 1000; in the absence of heparin the excess was 2 (SD 1) and was not significant. There was no interaction between aspirin and heparin in the main outcomes. INTERPRETATION: Neither heparin regimen offered any clinical advantage at 6 months. The results suggest that if heparin is given in routine clinical practice, the dose should not exceed 5000 IU subcutaneously twice daily. For aspirin, the IST suggests a small but worthwhile improvement at 6 months. Taking the IST together with the comparably large Chinese Acute Stroke Trial, aspirin produces a small but real reduction of about 10 deaths or recurrent strokes per 1000 during the first few weeks. Both trials suggest that aspirin should be started as soon as possible after the onset of ischaemic stroke; previous trials have already shown that continuation of low-dose aspirin gives protection in the longer term 0 (Anticoagulants) 0 (Platelet Aggregation Inhibitors) 50-78-2 (Aspirin) 9005-49-6 (Heparin) 0140-6736&lt;/p&gt;" NOTES_MODIFIED="2008-07-16 16:00:35 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>International Stroke Trial Collaborative Group</AU>
<TI>The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9065</NO>
<PG>1569-1581</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:00:35 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pince-1981" MODIFIED="2008-07-16 16:00:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Pince 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-07-16 16:00:42 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK">
<AU>Pince J</AU>
<SO>Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparatif de traitement preventif (These pour le doctorat d'etat en medecine)</SO>
<YR>1981</YR>
<PB>Université Paul Sabatier</PB>
<CY>Toulouse</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-TAIST-2001" MODIFIED="2008-07-16 16:00:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="TAIST 2001" YEAR="">
<REFERENCE MODIFIED="2008-07-16 16:00:59 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bath PMW, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Orgogozo JM, Ringelstein B, van der Sande JJ, Turpie AGG, for the TAIST Investigators</AU>
<TI>Tinzaparin in acute ishcaemic stroke (TAIST): a randomised aspirin-controlled trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<PG>702-710</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-07-16 16:02:18 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Biller-1989" MODIFIED="2008-07-16 16:01:12 +0100" MODIFIED_BY="Hazel Fraser" NAME="Biller 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-07-16 16:01:12 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;89187881&lt;/p&gt;" NOTES_MODIFIED="2008-07-16 16:01:12 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biller J, Bruno A, Adams HP, Jr., Godersky JC, Loftus CM, Mitchell VL, Banwart KJ, Jones MP</AU>
<TI>A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>4</NO>
<PG>441-447</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:01:12 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bur_x00e9_n-1981" MODIFIED="2008-07-16 16:01:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="Burén 1981" YEAR="">
<REFERENCE MODIFIED="2008-07-16 16:01:19 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;82062758&lt;/p&gt;" NOTES_MODIFIED="2008-07-16 16:01:19 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burén A, Ygge J</AU>
<TI>Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack</TI>
<SO>Stroke</SO>
<YR>1981</YR>
<VL>12</VL>
<NO>5</NO>
<PG>578-580</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:01:19 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1992" MODIFIED="2008-07-16 16:01:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chen 1992" YEAR="">
<REFERENCE MODIFIED="2008-07-16 16:01:26 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen KJ, Chen K</AU>
<TI>Combined traditional Chinese and Western medicine</TI>
<SO>Chin Med J</SO>
<YR>1992</YR>
<VL>105</VL>
<NO>10</NO>
<PG>870-873</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:01:26 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ECAD-1993" MODIFIED="2008-07-16 16:01:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="ECAD 1993" YEAR="">
<REFERENCE MODIFIED="2008-07-16 16:01:35 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Kramer G, Ringelstein EB, Thie A</AU>
<TI>European Carotid Artery Dissection (ECAD) Study [abstract]</TI>
<SO>Proceedings of the 2nd International Conference on Stroke</SO>
<YR>1993</YR>
<PB>World Federation of Neurology</PB>
<CY>Geneva</CY>
<IDENTIFIERS MODIFIED="2008-07-16 16:01:33 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-1989" MODIFIED="2008-07-16 16:01:44 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gao 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-07-16 16:01:44 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao B</AU>
<TI>The effects of ligustrazine, aspirin and betahistidine on platelet aggregation in patients with acute ischaemic stroke</TI>
<SO>Chinese Journal of Neurology and Psychiatry</SO>
<YR>1989</YR>
<VL>22</VL>
<NO>3</NO>
<PG>148-151</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:01:44 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garde-1983" MODIFIED="2008-07-16 16:01:52 +0100" MODIFIED_BY="Hazel Fraser" NAME="Garde 1983" YEAR="">
<REFERENCE MODIFIED="2008-07-16 16:01:52 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;84098747&lt;/p&gt;" NOTES_MODIFIED="2008-07-16 16:01:52 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J</AU>
<TI>Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation</TI>
<SO>Stroke</SO>
<YR>1983</YR>
<VL>14</VL>
<NO>5</NO>
<PG>677-681</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:01:50 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joseph-1987" MODIFIED="2008-07-16 16:02:04 +0100" MODIFIED_BY="Hazel Fraser" NAME="Joseph 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-07-16 16:02:04 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joseph R, Oster SB, Levine SR, D'Andrea G, Welch KMA</AU>
<TI>Controlled comparison of antithrombotic agents on whole blood platelet function in acute ischemic stroke [abstract]</TI>
<SO>Neurology</SO>
<YR>1987</YR>
<VL>37 (Suppl 1)</VL>
<PG>131</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:02:04 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsson-1980" MODIFIED="2008-07-16 16:02:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="Olsson 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-07-16 16:02:18 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;80124918&lt;/p&gt;" NOTES_MODIFIED="2008-07-16 16:02:18 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsson JE, Brechter C, Backlund H, Krook H, Muller R, Nitelius E, Olsson O, Tornberg A</AU>
<TI>Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks</TI>
<SO>Stroke</SO>
<YR>1980</YR>
<VL>11</VL>
<NO>1</NO>
<PG>4-9</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:02:15 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2008-07-16 16:02:27 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-AIST_x002d_ASH" MODIFIED="2008-07-16 16:02:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="AIST-ASH" YEAR="">
<REFERENCE MODIFIED="2008-07-16 16:02:27 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rha JS, Han SR, Song HJ, Choi NC, Kim JY, Kim J, Cho KH</AU>
<TI>Acute Ischemic Stroke Trial: Oral aspirin vs intravenous heparin on stroke rogression</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>2812</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FISS_x002d_tris" NAME="FISS-tris" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Wong L</AU>
<TI>A multi-centre, randomised, controlled study comparing nadroparin calcium (Fraxiparine) 3.800 anti-Xa IU/0.4 ml twice daily with aspirin 160 mg once daily for the treatment of acute ischaemic stroke (Protocol)</TI>
<SO>Unpublished</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-RAPID" NAME="RAPID" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chamorro A</AU>
<TI>Heparin in acute ischemic stroke: the case for a new clinical trial</TI>
<SO>Cerebrovasc Dis</SO>
<YR>1999</YR>
<VL>9 (Suppl 3)</VL>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-16 16:03:57 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-16 16:03:57 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2008-07-16 16:02:38 +0100" MODIFIED_BY="Hazel Fraser" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Matthews JN</AU>
<TI>Statistics notes. Interaction 1: Heterogeneity of effects</TI>
<SO>British Medical Journal</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7055</NO>
<PG>486</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:02:38 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-APT-1994" MODIFIED="2008-07-16 16:02:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="APT 1994" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists' Collaboration</AU>
<TI>Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration</TI>
<SO>British Medical Journal</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6923</NO>
<PG>235-246</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:02:49 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1990" MODIFIED="2008-07-16 16:02:58 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bamford 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bamford J, Sandercock P, Dennis M, Burn J, Warlow C</AU>
<TI>A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1990</YR>
<VL>53</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:02:58 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Bath-2001a" MODIFIED="2008-07-16 15:57:54 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bath 2001a" TYPE="COCHRANE_REVIEW">
<AU>Bath P, Bath F, Asplund K</AU>
<TI>Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-16 15:57:44 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Bath-2001b" MODIFIED="2008-07-16 15:58:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bath 2001b" TYPE="COCHRANE_REVIEW">
<AU>Bath P, Bath F</AU>
<TI>Prostacyclin and analogues for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-16 15:58:08 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Broderick-1989" MODIFIED="2008-07-16 16:03:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Broderick 1989" TYPE="JOURNAL_ARTICLE">
<AU>Broderick JP, Phillips SJ, Whisnant JP, O'Fallon WM, Bergstralh EJ</AU>
<TI>Incidence rates of stroke in the eighties: the end of the decline in stroke?</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>5</NO>
<PG>577-582</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:03:08 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Counsell-2001" MODIFIED="2008-07-16 15:57:16 +0100" MODIFIED_BY="Hazel Fraser" NAME="Counsell 2001" TYPE="COCHRANE_REVIEW">
<AU>Counsell C, Sandercock P</AU>
<TI>Low molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gubitz-2001a" MODIFIED="2008-07-16 15:56:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gubitz 2001a" TYPE="COCHRANE_REVIEW">
<AU>Gubitz G, Counsell C, Sandercock P, Signorini D</AU>
<TI>Anticoagulants for acute ischaemic stroke (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-16 15:54:15 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Gubitz-2001b" MODIFIED="2008-07-16 15:55:50 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gubitz 2001b" TYPE="COCHRANE_REVIEW">
<AU>Gubitz G, Sandercock P, Counsell C</AU>
<TI>Antiplatelet therapy for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-16 15:55:50 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Homer-1987" MODIFIED="2008-07-16 16:03:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="Homer 1987" TYPE="JOURNAL_ARTICLE">
<AU>Homer D, Whisnant JP, Schoenberg BS</AU>
<TI>Trends in the incidence rates of stroke in Rochester, Minnesota, since 1935</TI>
<SO>Annals of Neurology</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>2</NO>
<PG>245-251</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:03:19 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-IST-1997" MODIFIED="2008-07-16 16:03:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="IST 1997" TYPE="JOURNAL_ARTICLE">
<AU>International Stroke Trial Collaborative Group</AU>
<TI>The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9065</NO>
<PG>1569-1581</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:03:26 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2001" MODIFIED="2008-07-16 15:57:33 +0100" MODIFIED_BY="Hazel Fraser" NAME="Liu 2001" TYPE="COCHRANE_REVIEW">
<AU>Liu M, Counsell C, Wardlaw J</AU>
<TI>Fibrinogen depleting agents for acute ischaemic (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-16 15:57:33 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-MedStrategy-1995" NAME="MedStrategy 1995" TYPE="BOOK">
<AU>Dick E</AU>
<TI>Stroke: A focus of opportunity</TI>
<TO>Stroke: A focus of opportunity</TO>
<SO>Stroke: A focus of opportunity</SO>
<YR>1995</YR>
<PB>MedStrategy</PB>
<CY>St. Louis, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PEP-trial-2000" NAME="PEP trial 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pulmonary Embolism Prevention(PEP) Trial Collaborative Group</AU>
<TI>Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>1295-1302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ricci-2001" MODIFIED="2008-07-16 15:56:56 +0100" MODIFIED_BY="Hazel Fraser" NAME="Ricci 2001" TYPE="COCHRANE_REVIEW">
<AU>Ricci S, Celani MG, Cantisani AT, Righetti E</AU>
<TI>Piracetam for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-1992" NAME="Sandercock 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sandercock P, Celani MG, Ricci S</AU>
<TI>The likely public health impact of simple treatments for acute ischaemic stroke (abstract)</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>234</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-07-16 16:03:44 +0100" MODIFIED_BY="Hazel Fraser" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman, DG.</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medial Association</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-412</PG>
<IDENTIFIERS MODIFIED="2008-07-16 16:03:44 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2001" MODIFIED="2008-07-16 16:03:57 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wardlaw 2001" TYPE="COCHRANE_REVIEW">
<AU>Wardlaw JM, del Zoppo GJ, Yamaguchi T</AU>
<TI>Thrombolysis in acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-16 16:03:57 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-16 15:34:11 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-16 15:28:44 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-HAEST-2000">
<CHAR_METHODS>
<P>C: Sequentually numbered boxes (stratified by centre); Double blind design; E: Nil; Loss to FU: Nil</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Norwegian, 449 pts; Median age 80 yrs; 'Any' ischaemic stroke among pts with atrial fibrillation; CT in all; All randomised within 30 hrs of onset;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dalteparin 100 IU/kg sc x 2 vs Aspirin 160 mg po x 1; Duration 14 d or until prior discharge;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: Recurrent ischaemic stroke within 14 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>FU: 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-IST-1997">
<CHAR_METHODS>
<P>C: Centralised (telephone) randomisation; Open design, but blinded assessment of long-term outcome; E: Nil: Loss to FU: &lt;1%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>International, 19435 pts; 61% aged over 70 yrs; 'Any' ischaemic stroke; CT in 96% (67% before randomisation); All randomised within 48 hrs of onset;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UFH (5000 IU sc x 2 or 12500 IU sc x 2), Aspirin 300 mg po x 1, both, or neither; Duration 14 days or until prior discharge;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: Death or dependency at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>FU: 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pince-1981">
<CHAR_METHODS>
<P>C: Sealed envelopes; Open design; E: Treatment 0, Control 5; Loss to FU: Nil;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>French, 80 pts; Median age 62 yrs; Ischaemic stroke with lower limb paresis; No CT, but LP in all; 91% of pts randomised within 48 hrs of onset;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UFH 5000 IU sc x 3 vs Aspirin 333 mg po x 3/Dipyridamole 75 mg po x 3; Duration 10 days;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: DVT (symptomatic and asymptomatic) within 10 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>FU: 10 days. Iodine 125 fibrinogen scanning once daily for 10 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-TAIST-2001">
<CHAR_METHODS>
<P>C: Sequentually numbered boxes (stratification by centre and stroke severity); Double blind design; E: 2 pts; Loss to FU: 3.2%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>International, 1486 pts; Median age 74 yrs; 'Any' ischaemic stroke; CT in all; All randomised within 48 hrs of onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tinzaparin 175 IU/kg sc x 1, Tinzaparin 100 IU/kg sc x 1, or aspirin 300 mg po x 1; Duration 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: Independence (modified Rankin Scale &lt;3) at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>FU: 6 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AC: anticoagulant<BR/>AP: antiplatelet agent<BR/>C: concealment of allocation<BR/>DVT: deep vein thrombosis<BR/>E: exclusion after randomisation<BR/>FU: follow-up<BR/>LP: lumbar puncture<BR/>sc: subcutaneously<BR/>po: per os</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-16 15:34:11 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Biller-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only patients with transient ischaemic attacks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bur_x00e9_n-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised controlled trial. Only patients with transient ischaemic attacks.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Primary mode of action of agent unclear, but appeared to have both anticoagulant and antiplatelet actions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ECAD-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients with retinal or cerebral ischaemia due to internal carotid artery dissection only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gao-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Primary mode of action of agent not anticoagulant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garde-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Nearly half of the patients had TIA. Randomisation probably generally more than 14 days after stroke onset in most cases.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joseph-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only pharmacological and no clinical measures of outcome. Probably not randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olsson-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation at 2 months after stroke onset</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-07-16 15:31:01 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-AIST_x002d_ASH">
<CHAR_STUDY_NAME>
<P>Acute Ischemic Stroke Trial: oral Aspirin vs intravenous Heparin on stroke progression</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Ischaemic stroke, excluding 'cardioembolic stroke', 'basilar stroke', and TIA; CT before randomisation; Randomisation within 48 h;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UFH heparin iv with monitoring of aPTT for 6 days, followed by aspirin; Aspirin po 300 mg x 1. Duration of trial treatment unknown</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression of symptoms(NIHSS) during first week; Functional outcome (BI and mRS) at 3 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>August 1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Dr Joung-Ho Rha, Dept of Neurology, Inha Univ Hospital, Choong-ku Shinheung-dong 3-ka 7-206, Inchon, Korea. URL: http://aist.onnet.co.kr/aist1/Design.html</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Close-out expected in 2001</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-FISS_x002d_tris">
<CHAR_STUDY_NAME>
<P>FISS-tris</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Chinese pts with 'large artery' ischaemic stroke (confirmed by TCD or MRA), exluding pts with AF. CT before randomisation; Randomisation within 24 h;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Nadroparin 3,800 IU/0.4 ml sc x 2; Aspirin 160 mg po x 1</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death or dependency (BI&lt;85) at 6 months; NIHSS score at 10 days and 6 months; mRS and IST scale score at 6 months; Recurrent stroke, VTE</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Assoc Prof Lawrence Wong, Division of Neurology, Dept of Medicine and Therapeutics, The Chinese Univ of Hong Kong, The Prince of Wales Hospital, Hong Kong. E-mail: ks-wong@cuhk.edu.hk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-RAPID">
<CHAR_STUDY_NAME>
<P>Rapid Anticoagulation Preventing Ischemic Damage</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Ischaemic stroke. CT before randomisation; Randomisation within 12 h;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>UFH 40 IU/kg bolus, followed by infusion, monitored with aPTT; Aspirin po 160-325 mg; Duration 6 d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>mRS at 3 months; NIHSS at day 1, 7, and 90; Death, recurrent ischaemic stroke, VTE during treatment period</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not started, as of 2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Dr Angel Chamorro. E-mail: achamorro@clinic.ub.es</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>AF: atrial fibrillation<BR/>BI: Barthel Index<BR/>IST: International Stroke Study<BR/>MRA: magnetic resonance angiography<BR/>mRS: modified Rankin Scale<BR/>NIHSS: National Institute of Health Stroke Scale<BR/>TCD: transcranial doppler<BR/>TIA: transient ischaemic attack<BR/>UFH: unfractionated heparin<BR/>VTE: venous thromboembolism</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-HAEST-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-IST-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pince-1981">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-TAIST-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-16 15:33:24 +0100" MODIFIED_BY="Hazel Fraser">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Anticoagulants vs antiplatelet agents</NAME>
<DICH_OUTCOME CHI2="0.8070131889625034" CI_END="1.1536194065246472" CI_START="0.990934976557836" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.069187457633677" ESTIMABLE="YES" EVENTS_1="3802" EVENTS_2="3430" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.06206255326619677" LOG_CI_START="-0.003954842233810126" LOG_EFFECT_SIZE="0.02905385551619332" METHOD="MH" NO="1" P_CHI2="0.9375053953851744" P_Q="0.0" P_Z="0.08450286994190424" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5996" TOTAL_2="5531" WEIGHT="100.0" Z="1.7251365338629083">
<NAME>Death or dependency at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.175188031319688" CI_START="0.9303356577632376" DF="0" EFFECT_SIZE="1.0456191133071766" ESTIMABLE="YES" EVENTS_1="1526" EVENTS_2="1499" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.0701073597407738" LOG_CI_START="-0.03136033315132532" LOG_EFFECT_SIZE="0.01937351329472424" NO="1" P_CHI2="1.0" P_Z="0.4541930466842362" STUDIES="1" TAU2="0.0" TOTAL_1="2411" TOTAL_2="2408" WEIGHT="42.815794990199876" Z="0.7484429226561059">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.175188031319688" CI_START="0.9303356577632376" EFFECT_SIZE="1.0456191133071766" ESTIMABLE="YES" EVENTS_1="1526" EVENTS_2="1499" LOG_CI_END="0.0701073597407738" LOG_CI_START="-0.03136033315132532" LOG_EFFECT_SIZE="0.01937351329472424" ORDER="25620" O_E="0.0" SE="0.05960262507799942" STUDY_ID="STD-IST-1997" TOTAL_1="2411" TOTAL_2="2408" VAR="0.003552472916188565" WEIGHT="42.815794990199876"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.199998653366352" CI_START="0.9495711947600497" DF="0" EFFECT_SIZE="1.0674662313101702" ESTIMABLE="YES" EVENTS_1="1535" EVENTS_2="1499" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.07918075868438265" LOG_CI_START="-0.02247246817573052" LOG_EFFECT_SIZE="0.028354145254326082" NO="2" P_CHI2="1.0" P_Z="0.2742244097183173" STUDIES="1" TAU2="0.0" TOTAL_1="2407" TOTAL_2="2408" WEIGHT="42.22190860772379" Z="1.0933859204955996">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.199998653366352" CI_START="0.9495711947600497" EFFECT_SIZE="1.0674662313101702" ESTIMABLE="YES" EVENTS_1="1535" EVENTS_2="1499" LOG_CI_END="0.07918075868438265" LOG_CI_START="-0.02247246817573052" LOG_EFFECT_SIZE="0.028354145254326082" ORDER="25621" O_E="0.0" SE="0.059711608649218796" STUDY_ID="STD-IST-1997" TOTAL_1="2407" TOTAL_2="2408" VAR="0.003565476207477461" WEIGHT="42.22190860772379"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20626155161102755" CI_END="1.443874755256552" CI_START="0.8843554724334509" DF="1" EFFECT_SIZE="1.1299993545660287" ESTIMABLE="YES" EVENTS_1="440" EVENTS_2="289" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.15952952324748126" LOG_CI_START="-0.05337313240186699" LOG_EFFECT_SIZE="0.05307819542280715" NO="3" P_CHI2="0.6497134877505893" P_Z="0.3284370839993819" STUDIES="2" TAU2="0.0" TOTAL_1="692" TOTAL_2="470" WEIGHT="9.33361815230688" Z="0.9772668271871714">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="1.5549936577526147" CI_START="0.7140294017746716" EFFECT_SIZE="1.0537130497476568" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="146" LOG_CI_END="0.19172862203895957" LOG_CI_START="-0.14628390479861889" LOG_EFFECT_SIZE="0.022722358620170354" ORDER="25622" O_E="0.0" SE="0.19855023145338632" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="0.039422194410193276" WEIGHT="3.843581922426747"/>
<DICH_DATA CI_END="1.6223002850716546" CI_START="0.8632515987975801" EFFECT_SIZE="1.1834075015893197" ESTIMABLE="YES" EVENTS_1="292" EVENTS_2="143" LOG_CI_END="0.21013124449864973" LOG_CI_START="-0.06386260863640134" LOG_EFFECT_SIZE="0.07313431793112421" ORDER="25623" O_E="0.0" SE="0.160945345622976" STUDY_ID="STD-TAIST-2001" TOTAL_1="468" TOTAL_2="245" VAR="0.025903404277699202" WEIGHT="5.4900362298801335"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5872685737664494" CI_START="0.8485303588927056" DF="0" EFFECT_SIZE="1.1605367605367605" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="143" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.20065041776691644" LOG_CI_START="-0.07133261479154586" LOG_EFFECT_SIZE="0.06465890148768529" NO="4" P_CHI2="1.0" P_Z="0.3513934476277454" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="245" WEIGHT="5.628678249769456" Z="0.931889883009862">
<NAME>Low molecular-weight heparin, low dose</NAME>
<DICH_DATA CI_END="1.5872685737664494" CI_START="0.8485303588927056" EFFECT_SIZE="1.1605367605367605" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="143" LOG_CI_END="0.20065041776691644" LOG_CI_START="-0.07133261479154586" LOG_EFFECT_SIZE="0.06465890148768529" ORDER="25624" O_E="0.0" SE="0.1597641796625654" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="245" VAR="0.025524593103252474" WEIGHT="5.628678249769456"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9519763754659636" CI_END="1.2063645351343555" CI_START="1.0069184507658913" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.102139151276462" ESTIMABLE="YES" EVENTS_1="1293" EVENTS_2="1128" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.08147856126621066" LOG_CI_START="0.00299429893841904" LOG_EFFECT_SIZE="0.04223643010231488" METHOD="MH" NO="2" P_CHI2="0.9169884357693102" P_Q="0.0" P_Z="0.034900114171035036" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6035" TOTAL_2="5532" WEIGHT="99.99999999999999" Z="2.1095154463028485">
<NAME>Death at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.26089183935286" CI_START="0.959669884733522" DF="0" EFFECT_SIZE="1.1000181480926565" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="509" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.10067783392686758" LOG_CI_START="-0.017878133516813787" LOG_EFFECT_SIZE="0.041399850205026865" NO="1" P_CHI2="1.0" P_Z="0.1710485552465606" STUDIES="1" TAU2="0.0" TOTAL_1="2411" TOTAL_2="2408" WEIGHT="43.82261606239733" Z="1.368842363936704">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.26089183935286" CI_START="0.959669884733522" EFFECT_SIZE="1.1000181480926565" ESTIMABLE="YES" EVENTS_1="549" EVENTS_2="509" LOG_CI_END="0.10067783392686758" LOG_CI_START="-0.017878133516813787" LOG_EFFECT_SIZE="0.041399850205026865" ORDER="25625" O_E="0.0" SE="0.06964036213792205" STUDY_ID="STD-IST-1997" TOTAL_1="2411" TOTAL_2="2408" VAR="0.004849780038700926" WEIGHT="43.82261606239733"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2989914456510714" CI_START="0.9896244186955662" DF="0" EFFECT_SIZE="1.1338049454350403" ESTIMABLE="YES" EVENTS_1="561" EVENTS_2="509" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.11360629108937227" LOG_CI_START="-0.00452959715631843" LOG_EFFECT_SIZE="0.05453834696652693" NO="2" P_CHI2="1.0" P_Z="0.07034774088456192" STUDIES="1" TAU2="0.0" TOTAL_1="2407" TOTAL_2="2408" WEIGHT="43.48214448464985" Z="1.8096650800717415">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.2989914456510714" CI_START="0.9896244186955662" EFFECT_SIZE="1.1338049454350403" ESTIMABLE="YES" EVENTS_1="561" EVENTS_2="509" LOG_CI_END="0.11360629108937227" LOG_CI_START="-0.00452959715631843" LOG_EFFECT_SIZE="0.05453834696652693" ORDER="25626" O_E="0.0" SE="0.06939360553759678" STUDY_ID="STD-IST-1997" TOTAL_1="2407" TOTAL_2="2408" VAR="0.004815472489507583" WEIGHT="43.48214448464985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10094368002940118" CI_END="1.4412695921715606" CI_START="0.7514050791334274" DF="1" EFFECT_SIZE="1.0406619489335978" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="73" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.1587452240072926" LOG_CI_START="-0.1241258736429228" LOG_EFFECT_SIZE="0.0173096751821849" NO="3" P_CHI2="0.750700133423188" P_Z="0.8104299706932117" STUDIES="2" TAU2="0.0" TOTAL_1="710" TOTAL_2="470" WEIGHT="7.932533468897224" Z="0.23987137762035246">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="1.8049968474952784" CI_START="0.6759586645920194" EFFECT_SIZE="1.1045828437132785" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="37" LOG_CI_END="0.25647644772832473" LOG_CI_START="-0.17007986069810307" LOG_EFFECT_SIZE="0.0431982935151108" ORDER="25627" O_E="0.0" SE="0.25056128705746405" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="0.06278095857189289" WEIGHT="3.3785548447526836"/>
<DICH_DATA CI_END="1.5331489377730063" CI_START="0.6434632204980284" EFFECT_SIZE="0.993239625167336" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="36" LOG_CI_END="0.1855843464467128" LOG_CI_START="-0.19147627174521423" LOG_EFFECT_SIZE="-0.002945962649250693" ORDER="25628" O_E="0.0" SE="0.22148727360610015" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="245" VAR="0.04905661236946347" WEIGHT="4.553978624144541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4364008658040484" CI_START="0.608555153848915" DF="0" EFFECT_SIZE="0.9349487418452935" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="37" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.15727565822917283" LOG_CI_START="-0.2157000551877926" LOG_EFFECT_SIZE="-0.02921219847930988" NO="4" P_CHI2="1.0" P_Z="0.7588307814864937" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="246" WEIGHT="4.762705984055592" Z="0.30701654219868985">
<NAME>Low molecular-weight heparin, low dose</NAME>
<DICH_DATA CI_END="1.4364008658040484" CI_START="0.6085551538489149" EFFECT_SIZE="0.9349487418452935" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="37" LOG_CI_END="0.15727565822917283" LOG_CI_START="-0.21570005518779267" LOG_EFFECT_SIZE="-0.02921219847930988" ORDER="25629" O_E="0.0" SE="0.21908778032068305" STUDY_ID="STD-TAIST-2001" TOTAL_1="507" TOTAL_2="246" VAR="0.04799945548584387" WEIGHT="4.762705984055592"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.006671216623423" CI_END="1.1854112648699981" CI_START="0.9154798234675102" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0417389766633405" ESTIMABLE="YES" EVENTS_1="533" EVENTS_2="492" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.07386904998890624" LOG_CI_START="-0.038351222802245226" LOG_EFFECT_SIZE="0.01775891359333049" METHOD="MH" NO="3" P_CHI2="0.8482212127112249" P_Q="0.0" P_Z="0.5350401976934589" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6112" TOTAL_2="5609" WEIGHT="100.0" Z="0.6203305371082838">
<NAME>Death at end of treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2152785592158537" CI_START="0.8251022982569576" DF="0" EFFECT_SIZE="1.0013636363636365" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="226" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.08467583584747605" LOG_CI_START="-0.08349220319035326" LOG_EFFECT_SIZE="5.918163285614208E-4" NO="1" P_CHI2="1.0" P_Z="0.9889935349899656" STUDIES="1" TAU2="0.0" TOTAL_1="2426" TOTAL_2="2429" WEIGHT="45.39632193363275" Z="0.01379499572070506">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.2152785592158537" CI_START="0.8251022982569577" EFFECT_SIZE="1.0013636363636365" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="226" LOG_CI_END="0.08467583584747605" LOG_CI_START="-0.0834922031903532" LOG_EFFECT_SIZE="5.918163285614208E-4" ORDER="25630" O_E="0.0" SE="0.09878273857603966" STUDY_ID="STD-IST-1997" TOTAL_1="2426" TOTAL_2="2429" VAR="0.009758029440582194" WEIGHT="45.39632193363275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.22387820464500974" CI_END="1.2428467096650886" CI_START="0.8501440624105556" DF="1" EFFECT_SIZE="1.0279098942554599" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="233" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.0944175668943281" LOG_CI_START="-0.07050747404030804" LOG_EFFECT_SIZE="0.011955046427010016" NO="2" P_CHI2="0.6361006956822501" P_Z="0.7762978916817633" STUDIES="2" TAU2="0.0" TOTAL_1="2469" TOTAL_2="2464" WEIGHT="46.58885186844168" Z="0.28414678932510146">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="3.9840196486046766" CI_START="0.44622716115378813" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6003214716340772" LOG_CI_START="-0.35044399841747736" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1" O_E="0.0" SE="0.5584843434732633" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="35" VAR="0.3119047619047619" WEIGHT="1.2411858414436918"/>
<DICH_DATA CI_END="1.2364067719388583" CI_START="0.8407288568793111" EFFECT_SIZE="1.01955031852773" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="226" LOG_CI_END="0.09216137507747227" LOG_CI_START="-0.07534404575713384" LOG_EFFECT_SIZE="0.008408664660169242" ORDER="2" O_E="0.0" SE="0.09839351336345337" STUDY_ID="STD-IST-1997" TOTAL_1="2429" TOTAL_2="2429" VAR="0.009681283472004075" WEIGHT="45.347666026997985"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0948201529947437" CI_END="2.1485159660465456" CI_START="0.7430006047830799" DF="1" EFFECT_SIZE="1.2634669216717496" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="24" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.33213858535999585" LOG_CI_START="-0.12901083273491937" LOG_EFFECT_SIZE="0.10156387631253828" NO="3" P_CHI2="0.7581365220506682" P_Z="0.38795731201759054" STUDIES="2" TAU2="0.0" TOTAL_1="710" TOTAL_2="470" WEIGHT="5.4770002813709615" Z="0.8633277280288546">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="2.663209290206021" CI_START="0.6856363328792747" EFFECT_SIZE="1.3512931034482758" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.42540529712239195" LOG_CI_START="-0.16390617657072087" LOG_EFFECT_SIZE="0.13074956027583556" ORDER="25633" O_E="0.0" SE="0.34616447678617623" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="0.11982984498864716" WEIGHT="3.2066271182064203"/>
<DICH_DATA CI_END="2.6588107349220667" CI_START="0.48829536122017597" EFFECT_SIZE="1.1394230769230769" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.4246874235653217" LOG_CI_START="-0.3113174014706371" LOG_EFFECT_SIZE="0.0566850110473423" ORDER="25634" O_E="0.0" SE="0.4323328775087642" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="245" VAR="0.1869117169750081" WEIGHT="2.270373163164541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.049207416565872E-32" CI_END="3.3145287407076043" CI_START="0.7148829180041798" DF="0" EFFECT_SIZE="1.5393180236604038" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="9" I2="100.0" ID="CMP-001.03.04" LOG_CI_END="0.5204217891935256" LOG_CI_START="-0.14576508019665546" LOG_EFFECT_SIZE="0.18732835449843505" NO="4" P_CHI2="0.0" P_Z="0.2703470288277796" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="246" WEIGHT="2.5378259165546178" Z="1.102263779038981">
<NAME>Low molecular-weight heparin, low dose</NAME>
<DICH_DATA CI_END="3.3145287407076034" CI_START="0.7148829180041797" EFFECT_SIZE="1.5393180236604036" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="9" LOG_CI_END="0.5204217891935254" LOG_CI_START="-0.14576508019665552" LOG_EFFECT_SIZE="0.187328354498435" ORDER="25635" O_E="0.0" SE="0.3913214647579801" STUDY_ID="STD-TAIST-2001" TOTAL_1="507" TOTAL_2="246" VAR="0.15313248878033106" WEIGHT="2.5378259165546178"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4009727925271385" CI_START="0.30907119952453793" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0252525252525253" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5316031576302834" LOG_CI_START="-0.5099414623269197" LOG_EFFECT_SIZE="0.01083084765168183" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.9674850973307669" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="35" WEIGHT="100.0" Z="0.04076267288521708">
<NAME>Deep vein thrombosis (asymptomatic and symptomatic) during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4009727925271385" CI_START="0.30907119952453793" EFFECT_SIZE="1.0252525252525253" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5316031576302834" LOG_CI_START="-0.5099414623269197" LOG_EFFECT_SIZE="0.01083084765168183" ORDER="25636" O_E="0.0" SE="0.6118084654918805" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="35" VAR="0.3743095984475295" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6562086077161895" CI_END="0.5750539744251099" CI_START="0.06589032522646553" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.19465480573990995" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.24029139062361984" LOG_CI_START="-1.181178348823525" LOG_EFFECT_SIZE="-0.7107348697235724" METHOD="MH" NO="5" P_CHI2="0.4368769274833144" P_Q="0.0" P_Z="0.003065750569238266" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1217" TOTAL_2="716" WEIGHT="100.0" Z="2.961067182565843">
<NAME>Symptomatic deep vein thrombosis during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8630239024265108" CI_END="0.6317030250136452" CI_START="0.021523040820445892" DF="1" EFFECT_SIZE="0.11660261572438174" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.1994870434102256" LOG_CI_START="-1.667096370633607" LOG_EFFECT_SIZE="-0.9332917070219164" NO="1" P_CHI2="0.3528939445116417" P_Z="0.012674514188151373" STUDIES="2" TAU2="0.0" TOTAL_1="710" TOTAL_2="471" WEIGHT="67.75080509424754" Z="2.492786191668081">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="2.234205094607681" CI_START="0.02747462673084515" EFFECT_SIZE="0.24775784753363228" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34912303778943227" LOG_CI_START="-1.5610681991714568" LOG_EFFECT_SIZE="-0.6059725806910123" ORDER="25637" O_E="0.0" SE="1.1220557881899471" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="1.2590091918105635" WEIGHT="23.89817314011324"/>
<DICH_DATA CI_END="0.8194712078900077" CI_START="0.0024851322848859804" EFFECT_SIZE="0.04512753433616743" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.08646630075627386" LOG_CI_START="-2.604650488593856" LOG_EFFECT_SIZE="-1.3455583946750649" ORDER="25638" O_E="0.0" SE="1.4791938571485619" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="246" VAR="2.1880144670260404" WEIGHT="43.8526319541343"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.615000261747539" CI_START="0.07963847626036764" DF="0" EFFECT_SIZE="0.3586309523809524" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.2081725970544298" LOG_CI_START="-1.0988770580123437" LOG_EFFECT_SIZE="-0.44535223047895683" NO="2" P_CHI2="1.0" P_Z="0.18166675339700056" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="245" WEIGHT="32.24919490575247" Z="1.335640660306428">
<NAME>Low molecular-weight heparin, low dose</NAME>
<DICH_DATA CI_END="1.615000261747539" CI_START="0.07963847626036764" EFFECT_SIZE="0.3586309523809524" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.2081725970544298" LOG_CI_START="-1.0988770580123437" LOG_EFFECT_SIZE="-0.44535223047895683" ORDER="25639" O_E="0.0" SE="0.767767437386362" STUDY_ID="STD-TAIST-2001" TOTAL_1="507" TOTAL_2="245" VAR="0.5894668379108212" WEIGHT="32.24919490575247"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7261213071384003" CI_END="1.3169616119173788" CI_START="0.549456608704509" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8506546073925342" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.11957311590678546" LOG_CI_START="-0.2600665986804651" LOG_EFFECT_SIZE="-0.07024674138683985" METHOD="MH" NO="6" P_CHI2="0.8855926331115749" P_Q="0.0" P_Z="0.4682526932724852" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6112" TOTAL_2="5609" WEIGHT="100.0" Z="0.7253249744916394">
<NAME>Symptomatic pulmonary embolism during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3852817227125742" CI_START="0.32003631923350456" DF="0" EFFECT_SIZE="0.6658381662524164" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.14153810421456217" LOG_CI_START="-0.49480073309367817" LOG_EFFECT_SIZE="-0.176631314439558" NO="1" P_CHI2="1.0" P_Z="0.27656364675612877" STUDIES="1" TAU2="0.0" TOTAL_1="2426" TOTAL_2="2429" WEIGHT="41.04974750755418" Z="1.0880713058719362">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.3852817227125742" CI_START="0.32003631923350456" EFFECT_SIZE="0.6658381662524164" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.14153810421456217" LOG_CI_START="-0.49480073309367817" LOG_EFFECT_SIZE="-0.176631314439558" ORDER="25640" O_E="0.0" SE="0.3737885829629064" STUDY_ID="STD-IST-1997" TOTAL_1="2426" TOTAL_2="2429" VAR="0.13971790475341755" WEIGHT="41.04974750755418"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.027407414678145767" CI_END="2.0492557875417323" CI_START="0.5891796404410865" DF="1" EFFECT_SIZE="1.0988083491108236" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.31159617030197284" LOG_CI_START="-0.22975226895238735" LOG_EFFECT_SIZE="0.04092195067479277" NO="2" P_CHI2="0.8685096688839523" P_Z="0.7669875062080069" STUDIES="2" TAU2="0.0" TOTAL_1="2469" TOTAL_2="2464" WEIGHT="43.32445288408055" Z="0.29631765304502045">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="2.107426478228632" CI_START="0.5867908991848599" EFFECT_SIZE="1.1120335777870025" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.323752432332808" LOG_CI_START="-0.23151663045323698" LOG_EFFECT_SIZE="0.04611790093978544" ORDER="25641" O_E="0.0" SE="0.32616779610671287" STUDY_ID="STD-IST-1997" TOTAL_1="2429" TOTAL_2="2429" VAR="0.10638543121711024" WEIGHT="40.939425898957396"/>
<DICH_DATA CI_END="14.476063468083103" CI_START="0.052502277305121414" EFFECT_SIZE="0.8717948717948718" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1606504785379745" LOG_CI_START="-1.279821858506463" LOG_EFFECT_SIZE="-0.05958568998424408" ORDER="25642" O_E="0.0" SE="1.4335455313128034" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="35" VAR="2.055052790346908" WEIGHT="2.385026985123154"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.046896309186779984" CI_END="2.332555643854503" CI_START="0.08394325835631058" DF="1" EFFECT_SIZE="0.4424955604777848" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.367832012774687" LOG_CI_START="-1.0760141771461955" LOG_EFFECT_SIZE="-0.3540910821857543" NO="3" P_CHI2="0.8285548909473737" P_Z="0.3363866706466544" STUDIES="2" TAU2="0.0" TOTAL_1="710" TOTAL_2="471" WEIGHT="9.490015169346526" Z="0.9613292235358112">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="8.226307616223911" CI_START="0.013506802358323907" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9152049455731927" LOG_CI_START="-1.8694474550125177" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="25643" O_E="0.0" SE="1.6357186043557388" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="2.675575352635486" WEIGHT="3.4246880318958817"/>
<DICH_DATA CI_END="3.6005229453431205" CI_START="0.07058677603209194" EFFECT_SIZE="0.5041322314049587" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5563655829292296" LOG_CI_START="-1.1512766535405956" LOG_EFFECT_SIZE="-0.2974555353056831" ORDER="25644" O_E="0.0" SE="1.0030775026677734" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="246" VAR="1.006164476358217" WEIGHT="6.065327137450644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.311580654603963" CI_START="0.1757570635113809" DF="0" EFFECT_SIZE="0.9662027833001988" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.7252237804826235" LOG_CI_START="-0.7550872120698915" LOG_EFFECT_SIZE="-0.014931715793634009" NO="4" P_CHI2="1.0" P_Z="0.9684599956874584" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="245" WEIGHT="6.135784439018753" Z="0.039539833629753114">
<NAME>Low molecular weight-heparin, low dose</NAME>
<DICH_DATA CI_END="5.311580654603963" CI_START="0.1757570635113809" EFFECT_SIZE="0.9662027833001988" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7252237804826235" LOG_CI_START="-0.7550872120698915" LOG_EFFECT_SIZE="-0.014931715793634009" ORDER="25645" O_E="0.0" SE="0.8695420046829394" STUDY_ID="STD-TAIST-2001" TOTAL_1="507" TOTAL_2="245" VAR="0.7561032979080251" WEIGHT="6.135784439018753"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9577261801032089" CI_END="1.4845379311830713" CI_START="0.8166168796056219" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1010443828560705" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.17159129866028494" LOG_CI_START="-0.08798164738165482" LOG_EFFECT_SIZE="0.04180482563931508" METHOD="MH" NO="7" P_CHI2="0.619487337715686" P_Q="0.0" P_Z="0.5278355647931974" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1190" TOTAL_2="716" WEIGHT="100.00000000000001" Z="0.6313135007513121">
<NAME>Progression of symptoms during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Unfractionated heparin, high dose</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Unfractionated heparin, low dose</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7594020364024421" CI_END="1.708400500309499" CI_START="0.791897951055837" DF="1" EFFECT_SIZE="1.1631332063774378" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="46" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.2325896899390658" LOG_CI_START="-0.10133078071965124" LOG_EFFECT_SIZE="0.0656294546097073" NO="3" P_CHI2="0.38351575438251184" P_Z="0.44104418352605734" STUDIES="2" TAU2="0.0" TOTAL_1="703" TOTAL_2="470" WEIGHT="59.01137874323032" Z="0.7704311574925878">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="2.815070501000379" CI_START="0.7657765154111298" EFFECT_SIZE="1.468235294117647" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.44948927585238346" LOG_CI_START="-0.1158979565881586" LOG_EFFECT_SIZE="0.16679565963211246" ORDER="25646" O_E="0.0" SE="0.3321112590475121" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="0.11029788838612367" WEIGHT="18.28708867030494"/>
<DICH_DATA CI_END="1.649994573482074" CI_START="0.6381470795569573" EFFECT_SIZE="1.0261282660332542" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="29" LOG_CI_END="0.2174825159044114" LOG_CI_START="-0.1950792139459238" LOG_EFFECT_SIZE="0.011201650979243822" ORDER="25647" O_E="0.0" SE="0.24234080232758604" STUDY_ID="STD-TAIST-2001" TOTAL_1="479" TOTAL_2="245" VAR="0.05872906447277813" WEIGHT="40.72429007292538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.626290074310268" CI_START="0.6293132318604103" DF="0" EFFECT_SIZE="1.0116550116550116" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="29" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.21119801139124592" LOG_CI_START="-0.20113313673567307" LOG_EFFECT_SIZE="0.0050324373277864315" NO="4" P_CHI2="1.0" P_Z="0.9618420766344591" STUDIES="1" TAU2="0.0" TOTAL_1="487" TOTAL_2="246" WEIGHT="40.9886212567697" Z="0.047842109245069035">
<NAME>Low molecular weight-heparin, low dose</NAME>
<DICH_DATA CI_END="1.6262900743102677" CI_START="0.6293132318604104" EFFECT_SIZE="1.0116550116550116" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="29" LOG_CI_END="0.21119801139124586" LOG_CI_START="-0.20113313673567298" LOG_EFFECT_SIZE="0.0050324373277864315" ORDER="25648" O_E="0.0" SE="0.24220535748185337" STUDY_ID="STD-TAIST-2001" TOTAL_1="487" TOTAL_2="246" VAR="0.05866343519291239" WEIGHT="40.9886212567697"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3373597250431861" CI_END="1.3294269673240295" CI_START="0.8920992505406421" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.089027456586052" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="188" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.12366448415771787" LOG_CI_START="-0.04958682548455937" LOG_EFFECT_SIZE="0.03703882933657925" METHOD="MH" NO="8" P_CHI2="0.8550058201231174" P_Q="0.0" P_Z="0.4020146798176374" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6072" TOTAL_2="5574" WEIGHT="100.0" Z="0.8380285456902101">
<NAME>Recurrent stroke of ischaemic or unknown type during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5129881057891907" CI_START="0.8110464480608668" DF="0" EFFECT_SIZE="1.1077470962086347" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.17983551387221156" LOG_CI_START="-0.09095427333644387" LOG_EFFECT_SIZE="0.04444062026788384" NO="1" P_CHI2="1.0" P_Z="0.5200175766477333" STUDIES="1" TAU2="0.0" TOTAL_1="2426" TOTAL_2="2429" WEIGHT="40.53890554139354" Z="0.6433183176775953">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.5129881057891907" CI_START="0.8110464480608668" EFFECT_SIZE="1.1077470962086347" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="78" LOG_CI_END="0.17983551387221156" LOG_CI_START="-0.09095427333644387" LOG_EFFECT_SIZE="0.04444062026788384" ORDER="25649" O_E="0.0" SE="0.15906326143742905" STUDY_ID="STD-IST-1997" TOTAL_1="2426" TOTAL_2="2429" VAR="0.025301121139111902" WEIGHT="40.53890554139354"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3757640044757389" CI_START="0.7268688501419756" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="78" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.1385439423704042" LOG_CI_START="-0.1385439423704042" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="2429" TOTAL_2="2429" WEIGHT="40.70432104542931" Z="0.0">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.3757640044757389" CI_START="0.7268688501419756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="78" LOG_CI_END="0.1385439423704042" LOG_CI_START="-0.1385439423704042" LOG_EFFECT_SIZE="0.0" ORDER="25650" O_E="0.0" SE="0.16276279510390135" STUDY_ID="STD-IST-1997" TOTAL_1="2429" TOTAL_2="2429" VAR="0.026491727470034573" WEIGHT="40.70432104542931"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04058957099917673" CI_END="1.8558023316441359" CI_START="0.6351922808614477" DF="1" EFFECT_SIZE="1.0857215646126919" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.268531716038049" LOG_CI_START="-0.19709478828821458" LOG_EFFECT_SIZE="0.03571846387491721" NO="3" P_CHI2="0.8403323304068882" P_Z="0.7636434072594747" STUDIES="2" TAU2="0.0" TOTAL_1="710" TOTAL_2="471" WEIGHT="13.908600242777595" Z="0.3006998189642531">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="2.2432483326596926" CI_START="0.5732590944911133" EFFECT_SIZE="1.1340028694404591" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.35087735362486194" LOG_CI_START="-0.24164904666173728" LOG_EFFECT_SIZE="0.054614153481562296" ORDER="25651" O_E="0.0" SE="0.34805294058133346" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="0.12114084944731322" WEIGHT="8.369648804586296"/>
<DICH_DATA CI_END="2.4002669382324058" CI_START="0.427325339621804" EFFECT_SIZE="1.0127659574468084" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.38025954310940496" LOG_CI_START="-0.3692413535398537" LOG_EFFECT_SIZE="0.0055090947847756455" ORDER="25652" O_E="0.0" SE="0.44026053678104854" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="246" VAR="0.193829340246737" WEIGHT="5.5389514381913"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9769438887278925" CI_START="0.7176895001169187" DF="0" EFFECT_SIZE="1.68944099378882" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="7" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.5995494635060308" LOG_CI_START="-0.14406340750133265" LOG_EFFECT_SIZE="0.22774302800234902" NO="4" P_CHI2="1.0" P_Z="0.22993009080105486" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="245" WEIGHT="4.848173170399552" Z="1.2005390170560433">
<NAME>Low molecular-weight heparin, low dose</NAME>
<DICH_DATA CI_END="3.9769438887278925" CI_START="0.7176895001169186" EFFECT_SIZE="1.68944099378882" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="7" LOG_CI_END="0.5995494635060308" LOG_CI_START="-0.14406340750133273" LOG_EFFECT_SIZE="0.22774302800234902" ORDER="25653" O_E="0.0" SE="0.4368018813728023" STUDY_ID="STD-TAIST-2001" TOTAL_1="507" TOTAL_2="245" VAR="0.19079588357081964" WEIGHT="4.848173170399552"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.797764315414534" CI_END="3.45551005838621" CI_START="1.4908224692658878" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="2.269703072610257" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="31" I2="16.627834611454986" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.5385121614622066" LOG_CI_START="0.17342592969801487" LOG_EFFECT_SIZE="0.3559690455801108" METHOD="MH" NO="9" P_CHI2="0.3086847592256009" P_Q="0.0" P_Z="1.3235392474371082E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6072" TOTAL_2="5574" WEIGHT="100.0" Z="3.8220368134767013">
<NAME>Symptomatic intracranial haemorrhage (fatal or non-fatal) during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.8809639592893025E-31" CI_END="6.252169284498645" CI_START="1.7987269979275802" DF="0" EFFECT_SIZE="3.3534975305852357" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" I2="100.0" ID="CMP-001.09.01" LOG_CI_END="0.7960307285167455" LOG_CI_START="0.2549652532340304" LOG_EFFECT_SIZE="0.525497990875388" NO="1" P_CHI2="0.0" P_Z="1.4058079707990058E-4" STUDIES="1" TAU2="0.0" TOTAL_1="2426" TOTAL_2="2429" WEIGHT="40.46437444498121" Z="3.807144174282234">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="6.252169284498644" CI_START="1.7987269979275797" EFFECT_SIZE="3.3534975305852353" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" LOG_CI_END="0.7960307285167454" LOG_CI_START="0.2549652532340303" LOG_EFFECT_SIZE="0.5254979908753878" ORDER="25654" O_E="0.0" SE="0.31782453849836484" STUDY_ID="STD-IST-1997" TOTAL_1="2426" TOTAL_2="2429" VAR="0.1010124372716986" WEIGHT="40.46437444498121"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5673940486918485" CI_START="0.5914798398602884" DF="0" EFFECT_SIZE="1.2322994038700628" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.40949253015912196" LOG_CI_START="-0.2280600533803292" LOG_EFFECT_SIZE="0.0907162383893964" NO="2" P_CHI2="1.0" P_Z="0.5770085065588669" STUDIES="1" TAU2="0.0" TOTAL_1="2429" TOTAL_2="2429" WEIGHT="40.9484845936831" Z="0.5577596723679957">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="2.567394048691848" CI_START="0.5914798398602884" EFFECT_SIZE="1.2322994038700628" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.4094925301591219" LOG_CI_START="-0.2280600533803292" LOG_EFFECT_SIZE="0.0907162383893964" ORDER="25655" O_E="0.0" SE="0.3745015435072604" STUDY_ID="STD-IST-1997" TOTAL_1="2429" TOTAL_2="2429" VAR="0.14025140608932046" WEIGHT="40.9484845936831"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.478090697580728" CI_END="5.93427256684678" CI_START="0.7011066237323731" DF="1" EFFECT_SIZE="2.039744543723451" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.7733674900022155" LOG_CI_START="-0.15421592985454832" LOG_EFFECT_SIZE="0.3095757800738336" NO="3" P_CHI2="0.489288466959348" P_Z="0.1907871573555483" STUDIES="2" TAU2="0.0" TOTAL_1="710" TOTAL_2="471" WEIGHT="16.465584962763742" Z="1.3082540425836868">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="5.463245231699233" CI_START="0.4232562530022046" EFFECT_SIZE="1.5206422018348624" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7374506953678507" LOG_CI_START="-0.3733966170954765" LOG_EFFECT_SIZE="0.18202703913618712" ORDER="25656" O_E="0.0" SE="0.6525172101238383" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="0.42577870950779745" WEIGHT="12.315862011509532"/>
<DICH_DATA CI_END="29.265376559432223" CI_START="0.438029243211947" EFFECT_SIZE="3.580375782881002" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4663541165804366" LOG_CI_START="-0.3584968946519844" LOG_EFFECT_SIZE="0.5539286109642261" ORDER="25657" O_E="0.0" SE="1.0719265171561145" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="246" VAR="1.1490264581824379" WEIGHT="4.149722951254209"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="66.20452562457756" CI_START="0.17526252075318166" DF="0" EFFECT_SIZE="3.4063429137760157" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="1.8208876780590684" LOG_CI_START="-0.7563109462584391" LOG_EFFECT_SIZE="0.5322883659003148" NO="4" P_CHI2="1.0" P_Z="0.4181629665540926" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="245" WEIGHT="2.121555998571947" Z="0.8096124347657313">
<NAME>Low molecular-weight heparin, low dose</NAME>
<DICH_DATA CI_END="66.20452562457756" CI_START="0.17526252075318166" EFFECT_SIZE="3.4063429137760157" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8208876780590684" LOG_CI_START="-0.7563109462584391" LOG_EFFECT_SIZE="0.5322883659003148" ORDER="25658" O_E="0.0" SE="1.513859229263042" STUDY_ID="STD-TAIST-2001" TOTAL_1="507" TOTAL_2="245" VAR="2.2917697660248915" WEIGHT="2.121555998571947"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.152580566161893" CI_END="1.4573981675995251" CI_START="0.9944920815035543" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.203898225464062" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="203" I2="7.088262737312917" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.16357821914656534" LOG_CI_START="-0.0023986705315038057" LOG_EFFECT_SIZE="0.08058977430753075" METHOD="MH" NO="10" P_CHI2="0.34085788553696406" P_Q="0.0" P_Z="0.05699960672116715" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5079" TOTAL_2="5083" WEIGHT="100.0" Z="1.9033138344903244">
<NAME>Any recurrent stroke (ischaemic/unknown or haemorrhagic) during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.824918338767338" CI_START="1.0495316148226115" DF="0" EFFECT_SIZE="1.383947069437947" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="91" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.2612434354685423" LOG_CI_START="0.020995525277837365" LOG_EFFECT_SIZE="0.1411194803731898" NO="1" P_CHI2="1.0" P_Z="0.02130526000788149" STUDIES="1" TAU2="0.0" TOTAL_1="2426" TOTAL_2="2429" WEIGHT="44.846020645039836" Z="2.3025307385933727">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.824918338767338" CI_START="1.0495316148226115" EFFECT_SIZE="1.383947069437947" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="91" LOG_CI_END="0.2612434354685423" LOG_CI_START="0.020995525277837365" LOG_EFFECT_SIZE="0.1411194803731898" ORDER="25659" O_E="0.0" SE="0.14112281169235544" STUDY_ID="STD-IST-1997" TOTAL_1="2426" TOTAL_2="2429" VAR="0.019915647979956014" WEIGHT="44.846020645039836"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3733138186030387" CI_START="0.7618275239814998" DF="0" EFFECT_SIZE="1.0228530031612224" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="91" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.13776979005141038" LOG_CI_START="-0.11814334081480848" LOG_EFFECT_SIZE="0.009813224618300975" NO="2" P_CHI2="1.0" P_Z="0.8805174821872354" STUDIES="1" TAU2="0.0" TOTAL_1="2429" TOTAL_2="2429" WEIGHT="45.48028268875843" Z="0.15031324699103674">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.3733138186030387" CI_START="0.7618275239814998" EFFECT_SIZE="1.0228530031612224" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="91" LOG_CI_END="0.13776979005141038" LOG_CI_START="-0.11814334081480848" LOG_EFFECT_SIZE="0.009813224618300975" ORDER="25660" O_E="0.0" SE="0.15032463986124528" STUDY_ID="STD-IST-1997" TOTAL_1="2429" TOTAL_2="2429" VAR="0.022597497349413097" WEIGHT="45.48028268875843"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2508589224965108" CI_START="0.661678974016214" DF="0" EFFECT_SIZE="1.2203876525484565" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.35234827549748315" LOG_CI_START="-0.17935266558886231" LOG_EFFECT_SIZE="0.08649780495431042" NO="3" P_CHI2="1.0" P_Z="0.5236696324767998" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="225" WEIGHT="9.673696666201726" Z="0.6376990121771762">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="2.2508589224965108" CI_START="0.661678974016214" EFFECT_SIZE="1.2203876525484565" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.35234827549748315" LOG_CI_START="-0.17935266558886231" LOG_EFFECT_SIZE="0.08649780495431042" ORDER="25661" O_E="0.0" SE="0.3123237647562254" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="0.09754613403150204" WEIGHT="9.673696666201726"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low molecular-weight heparin, low dose</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.182259167448072" CI_END="3.11971701951901" CI_START="1.2049143090377405" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.9388119240831554" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="25" I2="22.81358629985806" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.49411520221234645" LOG_CI_START="0.08095616190229217" LOG_EFFECT_SIZE="0.2875356820573193" METHOD="MH" NO="11" P_CHI2="0.2691026484547768" P_Q="0.0" P_Z="0.006370965006133472" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6112" TOTAL_2="5609" WEIGHT="100.0" Z="2.728051554576096">
<NAME>Major extracranial haemorrhage during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.390817945301974" CI_START="1.4311284846541206" DF="0" EFFECT_SIZE="2.7775804429586293" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.7316546654057443" LOG_CI_START="0.1556786258432069" LOG_EFFECT_SIZE="0.44366664562447566" NO="1" P_CHI2="1.0" P_Z="0.0025321893557387594" STUDIES="1" TAU2="0.0" TOTAL_1="2426" TOTAL_2="2429" WEIGHT="45.61132940912673" Z="3.019468126577348">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="5.390817945301974" CI_START="1.4311284846541206" EFFECT_SIZE="2.7775804429586293" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" LOG_CI_END="0.7316546654057443" LOG_CI_START="0.1556786258432069" LOG_EFFECT_SIZE="0.44366664562447566" ORDER="25662" O_E="0.0" SE="0.33833117676641267" STUDY_ID="STD-IST-1997" TOTAL_1="2426" TOTAL_2="2429" VAR="0.11446798517214558" WEIGHT="45.61132940912673"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.143626463759544" CI_START="0.385217826136401" DF="0" EFFECT_SIZE="0.9087150963959563" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.33114910991001295" LOG_CI_START="-0.4142936239007163" LOG_EFFECT_SIZE="-0.041572256995351636" NO="2" P_CHI2="1.0" P_Z="0.8269548899166759" STUDIES="2" TAU2="0.0" TOTAL_1="2469" TOTAL_2="2464" WEIGHT="42.238556054214264" Z="0.21860868118038607">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="2.143626463759544" CI_START="0.385217826136401" EFFECT_SIZE="0.9087150963959563" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.33114910991001295" LOG_CI_START="-0.4142936239007163" LOG_EFFECT_SIZE="-0.041572256995351636" ORDER="25663" O_E="0.0" SE="0.43787675184146624" STUDY_ID="STD-IST-1997" TOTAL_1="2429" TOTAL_2="2429" VAR="0.191736049803233" WEIGHT="42.238556054214264"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="25664" O_E="0.0" SE="0.0" STUDY_ID="STD-Pince-1981" TOTAL_1="40" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4529765025928717" CI_END="19.35522358984941" CI_START="0.600510458505223" DF="1" EFFECT_SIZE="3.409254198855166" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="1.2867981926158076" LOG_CI_START="-0.2214794245116086" LOG_EFFECT_SIZE="0.5326593840520996" NO="3" P_CHI2="0.5009248677395043" P_Z="0.16625084462172302" STUDIES="2" TAU2="0.0" TOTAL_1="710" TOTAL_2="470" WEIGHT="6.978401464997948" Z="1.3843515237701889">
<NAME>Low molecular-weight heparin, high dose</NAME>
<DICH_DATA CI_END="138.7661241840471" CI_START="0.3659807585668689" EFFECT_SIZE="7.126410835214447" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1422834583698385" LOG_CI_START="-0.4365417470315428" LOG_EFFECT_SIZE="0.8528708556691478" ORDER="25665" O_E="0.0" SE="1.5148146910434157" STUDY_ID="STD-HAEST-2000" TOTAL_1="224" TOTAL_2="225" VAR="2.294663548200959" WEIGHT="1.893673986006481"/>
<DICH_DATA CI_END="18.214700302484925" CI_START="0.22510416411957862" EFFECT_SIZE="2.024896265560166" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.26042202992612" LOG_CI_START="-0.6476164710704355" LOG_EFFECT_SIZE="0.3064027794278422" ORDER="25666" O_E="0.0" SE="1.1207912604282826" STUDY_ID="STD-TAIST-2001" TOTAL_1="486" TOTAL_2="245" VAR="1.2561730494524181" WEIGHT="5.084727478991466"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.752607627130487" CI_START="0.08755795417242951" DF="0" EFFECT_SIZE="0.9702970297029703" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="1.0315137982742526" LOG_CI_START="-1.057704394454548" LOG_EFFECT_SIZE="-0.01309529809014773" NO="4" P_CHI2="1.0" P_Z="0.9803977446305797" STUDIES="1" TAU2="0.0" TOTAL_1="507" TOTAL_2="246" WEIGHT="5.171713071661059" Z="0.024570255718462844">
<NAME>Low molecular-weight heparin, low dose</NAME>
<DICH_DATA CI_END="10.752607627130487" CI_START="0.08755795417242951" EFFECT_SIZE="0.9702970297029703" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0315137982742526" LOG_CI_START="-1.057704394454548" LOG_EFFECT_SIZE="-0.01309529809014773" ORDER="25667" O_E="0.0" SE="1.2272171082057417" STUDY_ID="STD-TAIST-2001" TOTAL_1="507" TOTAL_2="246" VAR="1.5060618306728633" WEIGHT="5.171713071661059"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-16 15:33:24 +0100" MODIFIED_BY="Hazel Fraser" NO="2">
<NAME>Anticoagulants plus antiplatelet agents vs antiplatelet agents alone</NAME>
<DICH_OUTCOME CHI2="0.06207856244890039" CI_END="1.0855100126229396" CI_START="0.9206508992823526" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9996878359274495" ESTIMABLE="YES" EVENTS_1="3002" EVENTS_2="2998" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.03563383369263808" LOG_CI_START="-0.03590501829019905" LOG_EFFECT_SIZE="-1.3559229878048996E-4" METHOD="MH" NO="1" P_CHI2="0.8032403489087004" P_Q="0.0" P_Z="0.994072013447205" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4823" TOTAL_2="4816" WEIGHT="100.0" Z="0.007429697704808346">
<NAME>Death or dependency at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6056399600093015E-30" CI_END="1.1113997133154785" CI_START="0.8806001113532098" DF="0" EFFECT_SIZE="0.9892920252905791" ESTIMABLE="YES" EVENTS_1="1496" EVENTS_2="1499" I2="100.0" ID="CMP-002.01.01" LOG_CI_END="0.04587028042351748" LOG_CI_START="-0.055221263959298515" LOG_EFFECT_SIZE="-0.004675491767890509" NO="1" P_CHI2="0.0" P_Z="0.8561344822695978" STUDIES="1" TAU2="0.0" TOTAL_1="2413" TOTAL_2="2408" WEIGHT="50.34138571081858" Z="0.18129697258115302">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.1113997133154785" CI_START="0.8806001113532097" EFFECT_SIZE="0.989292025290579" ESTIMABLE="YES" EVENTS_1="1496" EVENTS_2="1499" LOG_CI_END="0.04587028042351748" LOG_CI_START="-0.05522126395929857" LOG_EFFECT_SIZE="-0.004675491767890558" ORDER="25668" O_E="0.0" SE="0.05938167358168135" STUDY_ID="STD-IST-1997" TOTAL_1="2413" TOTAL_2="2408" VAR="0.0035261831573613527" WEIGHT="50.34138571081858"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.13512864921408" CI_START="0.899067913708676" DF="0" EFFECT_SIZE="1.0102265817329548" ESTIMABLE="YES" EVENTS_1="1506" EVENTS_2="1499" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.055045084857392346" LOG_CI_START="-0.04620750133137939" LOG_EFFECT_SIZE="0.004418791763006468" NO="2" P_CHI2="1.0" P_Z="0.8641682160499831" STUDIES="1" TAU2="0.0" TOTAL_1="2410" TOTAL_2="2408" WEIGHT="49.65861428918142" Z="0.17107064691717164">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.13512864921408" CI_START="0.899067913708676" EFFECT_SIZE="1.0102265817329548" ESTIMABLE="YES" EVENTS_1="1506" EVENTS_2="1499" LOG_CI_END="0.055045084857392346" LOG_CI_START="-0.04620750133137939" LOG_EFFECT_SIZE="0.004418791763006468" ORDER="25669" O_E="0.0" SE="0.05947627033566953" STUDY_ID="STD-IST-1997" TOTAL_1="2410" TOTAL_2="2408" VAR="0.0035374267330416436" WEIGHT="49.65861428918142"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6408131716843082" CI_END="1.1511946422488526" CI_START="0.9478324386463046" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0445762897554636" ESTIMABLE="YES" EVENTS_1="1055" EVENTS_2="1018" I2="39.054609186645436" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.06114875969229672" LOG_CI_START="-0.023268432074668968" LOG_EFFECT_SIZE="0.01894016380881388" METHOD="MH" NO="2" P_CHI2="0.2002139984777087" P_Q="0.0" P_Z="0.37913565022858775" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4823" TOTAL_2="4816" WEIGHT="100.0" Z="0.879490022104499">
<NAME>Death at end of follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2741492205345624" CI_START="0.970185594458018" DF="0" EFFECT_SIZE="1.1118278728978441" ESTIMABLE="YES" EVENTS_1="554" EVENTS_2="509" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.10522029288141853" LOG_CI_START="-0.013145178167838644" LOG_EFFECT_SIZE="0.04603755735678994" NO="1" P_CHI2="1.0" P_Z="0.12735065004828527" STUDIES="1" TAU2="0.0" TOTAL_1="2413" TOTAL_2="2408" WEIGHT="49.32095907086974" Z="1.5246330463713653">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.2741492205345624" CI_START="0.970185594458018" EFFECT_SIZE="1.1118278728978441" ESTIMABLE="YES" EVENTS_1="554" EVENTS_2="509" LOG_CI_END="0.10522029288141853" LOG_CI_START="-0.013145178167838644" LOG_EFFECT_SIZE="0.04603755735678994" ORDER="25670" O_E="0.0" SE="0.06952846361286492" STUDY_ID="STD-IST-1997" TOTAL_1="2413" TOTAL_2="2408" VAR="0.004834207252365481" WEIGHT="49.32095907086974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1248500249540732" CI_START="0.8522820414423125" DF="0" EFFECT_SIZE="0.9791268945260841" ESTIMABLE="YES" EVENTS_1="501" EVENTS_2="509" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.051094622290265686" LOG_CI_START="-0.06941666254259023" LOG_EFFECT_SIZE="-0.009161020126162286" NO="2" P_CHI2="1.0" P_Z="0.7657147150867758" STUDIES="1" TAU2="0.0" TOTAL_1="2410" TOTAL_2="2408" WEIGHT="50.67904092913025" Z="0.2979848656302664">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.1248500249540732" CI_START="0.8522820414423125" EFFECT_SIZE="0.9791268945260841" ESTIMABLE="YES" EVENTS_1="501" EVENTS_2="509" LOG_CI_END="0.051094622290265686" LOG_CI_START="-0.06941666254259023" LOG_EFFECT_SIZE="-0.009161020126162286" ORDER="25671" O_E="0.0" SE="0.07078892525130037" STUDY_ID="STD-IST-1997" TOTAL_1="2410" TOTAL_2="2408" VAR="0.005011071938234191" WEIGHT="50.67904092913025"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3944094724344536" CI_END="1.0593664265580385" CI_START="0.8019039782267142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.92168874998923" ESTIMABLE="YES" EVENTS_1="420" EVENTS_2="452" I2="28.285054012568278" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.025046205156472722" LOG_CI_START="-0.09587763199377895" LOG_EFFECT_SIZE="-0.03541571341865312" METHOD="MH" NO="3" P_CHI2="0.2376620643876569" P_Q="0.0" P_Z="0.2509464601639999" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4862" TOTAL_2="4858" WEIGHT="100.0" Z="1.1480535918009875">
<NAME>Death at end of treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2645006725334107E-30" CI_END="1.2130630441011765" CI_START="0.8236115754282556" DF="0" EFFECT_SIZE="0.999546279491833" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="226" I2="100.0" ID="CMP-002.03.01" LOG_CI_END="0.08388337217223647" LOG_CI_START="-0.08427755823019618" LOG_EFFECT_SIZE="-1.970930289798596E-4" NO="1" P_CHI2="0.0" P_Z="0.9963342505109226" STUDIES="1" TAU2="0.0" TOTAL_1="2430" TOTAL_2="2429" WEIGHT="49.62757698852969" Z="0.004594351820960735">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.2130630441011767" CI_START="0.8236115754282556" EFFECT_SIZE="0.9995462794918331" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="226" LOG_CI_END="0.08388337217223656" LOG_CI_START="-0.08427755823019618" LOG_EFFECT_SIZE="-1.9709302897981138E-4" ORDER="25672" O_E="0.0" SE="0.09877856292841938" STUDY_ID="STD-IST-1997" TOTAL_1="2430" TOTAL_2="2429" VAR="0.009757204494203708" WEIGHT="49.62757698852969"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.837689265219294E-30" CI_END="1.0327317170515529" CI_START="0.6913658062545068" DF="0" EFFECT_SIZE="0.8449824827793462" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="226" I2="100.0" ID="CMP-002.03.02" LOG_CI_END="0.013987515191681047" LOG_CI_START="-0.16029210370915814" LOG_EFFECT_SIZE="-0.07315229425873855" NO="2" P_CHI2="0.0" P_Z="0.09989676342411764" STUDIES="1" TAU2="0.0" TOTAL_1="2432" TOTAL_2="2429" WEIGHT="50.3724230114703" Z="1.6453543224142702">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.032731717051553" CI_START="0.6913658062545069" EFFECT_SIZE="0.8449824827793463" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="226" LOG_CI_END="0.01398751519168114" LOG_CI_START="-0.16029210370915806" LOG_EFFECT_SIZE="-0.0731522942587385" ORDER="25673" O_E="0.0" SE="0.10237271084037991" STUDY_ID="STD-IST-1997" TOTAL_1="2432" TOTAL_2="2429" VAR="0.010480171924808039" WEIGHT="50.3724230114703"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7537205350739121" CI_END="0.99669433638816" CI_START="0.3386984269729592" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5810153215772603" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.0014380095652429437" LOG_CI_START="-0.4701868203572891" LOG_EFFECT_SIZE="-0.23581241496126604" METHOD="MH" NO="4" P_CHI2="0.38530087171589045" P_Q="0.0" P_Z="0.04861081788014378" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4862" TOTAL_2="4858" WEIGHT="100.0" Z="1.9719893887327091">
<NAME>Symptomatic pulmonary embolism during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0194353499366131" CI_START="0.19200892573766232" DF="0" EFFECT_SIZE="0.4424259106340031" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.008359689107727284" LOG_CI_START="-0.7166785821896118" LOG_EFFECT_SIZE="-0.3541594465409423" NO="1" P_CHI2="1.0" P_Z="0.055522195797903566" STUDIES="1" TAU2="0.0" TOTAL_1="2430" TOTAL_2="2429" WEIGHT="50.041273394189545" Z="1.914767226736416">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.0194353499366131" CI_START="0.19200892573766232" EFFECT_SIZE="0.4424259106340031" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="0.008359689107727284" LOG_CI_START="-0.7166785821896118" LOG_EFFECT_SIZE="-0.3541594465409423" ORDER="25674" O_E="0.0" SE="0.4258910695573825" STUDY_ID="STD-IST-1997" TOTAL_1="2430" TOTAL_2="2429" VAR="0.1813832031287312" WEIGHT="50.041273394189545"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4723671178880449" CI_START="0.3519235003066531" DF="0" EFFECT_SIZE="0.7198337237609664" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.1680161098618089" LOG_CI_START="-0.45355173142359956" LOG_EFFECT_SIZE="-0.14276781078089532" NO="2" P_CHI2="1.0" P_Z="0.3679246765773023" STUDIES="1" TAU2="0.0" TOTAL_1="2432" TOTAL_2="2429" WEIGHT="49.958726605810455" Z="0.900367582413897">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.4723671178880449" CI_START="0.3519235003066531" EFFECT_SIZE="0.7198337237609664" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.1680161098618089" LOG_CI_START="-0.45355173142359956" LOG_EFFECT_SIZE="-0.14276781078089532" ORDER="25675" O_E="0.0" SE="0.36511202678148547" STUDY_ID="STD-IST-1997" TOTAL_1="2432" TOTAL_2="2429" VAR="0.13330679210048416" WEIGHT="49.958726605810455"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.771586878936186" CI_END="0.9632503697043469" CI_START="0.5937366643662945" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7562519827794562" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="156" I2="43.55343156523678" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.016260815628714946" LOG_CI_START="-0.22640613173705024" LOG_EFFECT_SIZE="-0.12133347368288258" METHOD="MH" NO="5" P_CHI2="0.1831859376356787" P_Q="0.0" P_Z="0.023618203944893817" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4862" TOTAL_2="4858" WEIGHT="100.0" Z="2.2632837404283763">
<NAME>Recurrent stroke of ischaemic or unknown type during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.37677674968539E-31" CI_END="1.2239290948730897" CI_START="0.6339660501344784" DF="0" EFFECT_SIZE="0.8808686019613594" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="78" I2="100.0" ID="CMP-002.05.01" LOG_CI_END="0.08775625882480798" LOG_CI_START="-0.19793399863883324" LOG_EFFECT_SIZE="-0.055088869907012644" NO="1" P_CHI2="0.0" P_Z="0.4497277633770784" STUDIES="1" TAU2="0.0" TOTAL_1="2430" TOTAL_2="2429" WEIGHT="49.78890899940432" Z="0.7558689744994084">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.2239290948730894" CI_START="0.6339660501344784" EFFECT_SIZE="0.8808686019613593" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="78" LOG_CI_END="0.08775625882480789" LOG_CI_START="-0.19793399863883324" LOG_EFFECT_SIZE="-0.0550888699070127" ORDER="25676" O_E="0.0" SE="0.16781587142372503" STUDY_ID="STD-IST-1997" TOTAL_1="2430" TOTAL_2="2429" VAR="0.02816216670170421" WEIGHT="49.78890899940432"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9064973015840895" CI_START="0.4415765800466078" DF="0" EFFECT_SIZE="0.6326831578720747" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="78" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="-0.04263348435267999" LOG_CI_START="-0.35499396839988184" LOG_EFFECT_SIZE="-0.19881372637628095" NO="2" P_CHI2="1.0" P_Z="0.01259615861620079" STUDIES="1" TAU2="0.0" TOTAL_1="2432" TOTAL_2="2429" WEIGHT="50.21109100059568" Z="2.4949874470730276">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="0.9064973015840895" CI_START="0.4415765800466078" EFFECT_SIZE="0.6326831578720747" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="78" LOG_CI_END="-0.04263348435267999" LOG_CI_START="-0.35499396839988184" LOG_EFFECT_SIZE="-0.19881372637628095" ORDER="25677" O_E="0.0" SE="0.18348209453865935" STUDY_ID="STD-IST-1997" TOTAL_1="2432" TOTAL_2="2429" VAR="0.033665679016293526" WEIGHT="50.21109100059568"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.797032304224701" CI_END="3.7433501341636854" CI_START="1.489742740031428" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="2.3614886588264663" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="26" I2="64.24782086036056" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.5732604507381104" LOG_CI_START="0.17311127765314438" LOG_EFFECT_SIZE="0.3731858641956274" METHOD="MH" MODIFIED="2008-07-16 15:33:24 +0100" MODIFIED_BY="Hazel Fraser" NO="6" P_CHI2="0.09443905572064282" P_Q="0.0" P_Z="2.563902788631185E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4862" TOTAL_2="4858" WEIGHT="100.0" Z="3.655790902797025">
<NAME>Symptomatic intracranial haemorrhage (fatal or non-fatal) during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.104366112033572" CI_START="1.7502356211143537" DF="0" EFFECT_SIZE="3.268650947042907" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="13" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.7856405727298815" LOG_CI_START="0.2430965184357713" LOG_EFFECT_SIZE="0.5143685455828264" MODIFIED="2008-07-16 15:33:24 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="2.021155734513046E-4" STUDIES="1" TAU2="0.0" TOTAL_1="2430" TOTAL_2="2429" WEIGHT="49.749925373406185" Z="3.7163574686455956">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="6.104366112033572" CI_START="1.7502356211143537" EFFECT_SIZE="3.268650947042907" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="13" LOG_CI_END="0.7856405727298815" LOG_CI_START="0.2430965184357713" LOG_EFFECT_SIZE="0.5143685455828264" ORDER="25678" O_E="0.0" SE="0.3186930631287425" STUDY_ID="STD-IST-1997" TOTAL_1="2430" TOTAL_2="2429" VAR="0.10156526848638067" WEIGHT="49.749925373406185"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.969659679097585" CI_START="0.7210959079435414" DF="0" EFFECT_SIZE="1.4633555420956996" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.4727066823278082" LOG_CI_START="-0.14200696895520704" LOG_EFFECT_SIZE="0.1653498566863006" MODIFIED="2008-07-16 15:33:24 +0100" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Z="0.2916957773834702" STUDIES="1" TAU2="0.0" TOTAL_1="2432" TOTAL_2="2429" WEIGHT="50.25007462659381" Z="1.0544088724159528">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="2.969659679097585" CI_START="0.7210959079435414" EFFECT_SIZE="1.4633555420956996" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.4727066823278082" LOG_CI_START="-0.14200696895520704" LOG_EFFECT_SIZE="0.1653498566863006" ORDER="25679" O_E="0.0" SE="0.361085841645292" STUDY_ID="STD-IST-1997" TOTAL_1="2432" TOTAL_2="2429" VAR="0.13038298503668888" WEIGHT="50.25007462659381"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.970740845529537" CI_END="1.2119020665267255" CI_START="0.7958643032106898" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9820944932825392" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="182" I2="79.88227447223777" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.0834675260303592" LOG_CI_START="-0.09916097421029511" LOG_EFFECT_SIZE="-0.007846724089967961" METHOD="MH" NO="7" P_CHI2="0.025779763029403435" P_Q="0.0" P_Z="0.8662515777317342" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4862" TOTAL_2="4858" WEIGHT="100.00000000000001" Z="0.16842164933396853">
<NAME>Any recurrent stroke (ischaemic/unknown or haemorrhagic) during treatment period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6176269943157213" CI_START="0.9173546018302907" DF="0" EFFECT_SIZE="1.2181697612732096" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="91" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.20887838564093028" LOG_CI_START="-0.03746275609682409" LOG_EFFECT_SIZE="0.08570781477205311" NO="1" P_CHI2="1.0" P_Z="0.1726197713282072" STUDIES="1" TAU2="0.0" TOTAL_1="2430" TOTAL_2="2429" WEIGHT="49.551179808093714" Z="1.3638341444863797">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="1.6176269943157213" CI_START="0.9173546018302907" EFFECT_SIZE="1.2181697612732096" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="91" LOG_CI_END="0.20887838564093028" LOG_CI_START="-0.03746275609682409" LOG_EFFECT_SIZE="0.08570781477205311" ORDER="25680" O_E="0.0" SE="0.1447020060650749" STUDY_ID="STD-IST-1997" TOTAL_1="2430" TOTAL_2="2429" VAR="0.020938670559256974" WEIGHT="49.551179808093714"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.680858779985494E-31" CI_END="1.031135862637662" CI_START="0.5458346171920679" DF="0" EFFECT_SIZE="0.7502197337152903" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="91" I2="100.0" ID="CMP-002.07.02" LOG_CI_END="0.013315891768917345" LOG_CI_START="-0.26293892454968926" LOG_EFFECT_SIZE="-0.12481151639038596" NO="2" P_CHI2="0.0" P_Z="0.07655776770609461" STUDIES="1" TAU2="0.0" TOTAL_1="2432" TOTAL_2="2429" WEIGHT="50.4488201919063" Z="1.7710176440787062">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="1.0311358626376619" CI_START="0.5458346171920678" EFFECT_SIZE="0.7502197337152902" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="91" LOG_CI_END="0.013315891768917251" LOG_CI_START="-0.2629389245496893" LOG_EFFECT_SIZE="-0.12481151639038601" ORDER="25681" O_E="0.0" SE="0.16227344658894477" STUDY_ID="STD-IST-1997" TOTAL_1="2432" TOTAL_2="2429" VAR="0.02633267146785511" WEIGHT="50.4488201919063"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.346315911073548" CI_END="6.008070244005522" CI_START="2.3869519097534035" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="3.7869479456234374" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="23" I2="81.29553104168888" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.778735001626879" LOG_CI_START="0.3778436693045683" LOG_EFFECT_SIZE="0.5782893354657236" METHOD="MH" NO="8" P_CHI2="0.020766169490825215" P_Q="0.0" P_Z="1.5627222452632384E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4862" TOTAL_2="4858" WEIGHT="100.0" Z="5.654531184750892">
<NAME>Major extracranial haemorrhage during treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.429196127613942" CI_START="3.032025857324058" DF="0" EFFECT_SIZE="5.623307952622674" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="12" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="1.0182508347164745" LOG_CI_START="0.48173290066887847" LOG_EFFECT_SIZE="0.7499918676926765" NO="1" P_CHI2="1.0" P_Z="4.262416410888637E-8" STUDIES="1" TAU2="0.0" TOTAL_1="2430" TOTAL_2="2429" WEIGHT="51.68240763640431" Z="5.479619435219741">
<NAME>Unfractionated heparin, high dose</NAME>
<DICH_DATA CI_END="10.429196127613942" CI_START="3.032025857324058" EFFECT_SIZE="5.623307952622674" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="12" LOG_CI_END="1.0182508347164745" LOG_CI_START="0.48173290066887847" LOG_EFFECT_SIZE="0.7499918676926765" ORDER="25682" O_E="0.0" SE="0.3151532902661638" STUDY_ID="STD-IST-1997" TOTAL_1="2430" TOTAL_2="2429" VAR="0.0993215963655889" WEIGHT="51.68240763640431"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.69633895418867E-32" CI_END="3.8122092202144393" CI_START="0.8714768996922673" DF="0" EFFECT_SIZE="1.8227046585255537" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" I2="100.00000000000001" ID="CMP-002.08.02" LOG_CI_END="0.5811767274047014" LOG_CI_START="-0.05974412027991044" LOG_EFFECT_SIZE="0.26071630356239545" NO="2" P_CHI2="0.0" P_Z="0.1108098312527933" STUDIES="1" TAU2="0.0" TOTAL_1="2432" TOTAL_2="2429" WEIGHT="48.31759236359569" Z="1.594563718782823">
<NAME>Unfractionated heparin, low dose</NAME>
<DICH_DATA CI_END="3.81220922021444" CI_START="0.8714768996922673" EFFECT_SIZE="1.822704658525554" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.5811767274047015" LOG_CI_START="-0.05974412027991044" LOG_EFFECT_SIZE="0.2607163035623955" ORDER="25683" O_E="0.0" SE="0.3764800785393042" STUDY_ID="STD-IST-1997" TOTAL_1="2432" TOTAL_2="2429" VAR="0.14173724953696065" WEIGHT="48.31759236359569"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2011-03-07 12:13:06 +0000" MODIFIED_BY="Hazel Fraser">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-03-07 12:13:06 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2011-03-07 12:12:56 +0000" MODIFIED_BY="Hazel Fraser">Feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-03-07 12:13:06 +0000" MODIFIED_BY="Hazel Fraser">
<P>Feedback received for this review, and other reviews and protocols of anticoagulants, is available on the Cochrane Editorial Unit website at <A HREF="http://www.editorial-unit.cochrane.org/anticoagulants-feedback">http://www.editorial-unit.cochrane.org/anticoagulants-feedback</A>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY/>
<FEEDBACK_CONTRIBUTORS/>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2008-07-16 15:21:33 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2008-07-16 15:21:33 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-07-16 15:21:05 +0100" MODIFIED_BY="Hazel Fraser">Central/CCTR search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-16 15:21:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>Central/CCTR (2001, issue 3) was searched using the following search strategy:</P>
<P>CEREBROVASCULAR-DISORDERS*:ME<BR/>((((((STROKE* or APOPLE*) OR (CEREBRAL and VASC*)) OR CEREBROVASC*) OR CVA) OR (TRANSIENT AND ISCH*)) OR TIA*)<BR/>(((((BRAIN or CEREBR*) or CEREBELL*) or VERTEBROBASIL*) or HEMISPHER*) or INTRACRAN*)<BR/>(((((INTRACEREBRAL or INFRATENTORIAL) or SUPRATENTORIAL) OR (MIDDLE and CEREBR*)) OR MCA) OR (ANTERIOR AND CIRCULATION))<BR/>(#3 or #4)<BR/>(((((ISCH* or INFARCT*) or THROMBO*) or EMBOLI*) or OCCLUS*) or HYPOX*)<BR/>(#5 and #6)<BR/>((#1 or #2) or #7)<BR/>ANTICOAGULANTS*:ME<BR/>ANTICOAGULANT*<BR/>(((ACENOCOUMAROL* or DICOUMAROL*) OR (ETHYL and BISCOUMACETATE*)) OR PHENPROCOUMON*)<BR/>((((((WARFARIN* or ANCROD*) OR (CITRIC and ACID*)) OR COUMARIN*) OR CHROMONAR*) OR COUMESTRO*) OR ESCULI*)<BR/>((((OCHRATOXIN* or UMBELLIFERONE*) OR (DERMATAN and SULFATE*)) OR DEXTRAN*) OR (EDETIC AND ACID*))</P>
<P>(((((ENOXAPARIN* or GABEXATE*) or HEPARIN*) or LMWH*) or NADROPARIN*) OR (PENTOSAN AND (SULFURIC and POLYESTER*)))<BR/>PHENINDIONE* OR PROTEIN C OR PROTEIN S OR TEDELPARIN*<BR/>(((PHENINDIONE* or PROTEIN-C) or PROTEIN-S) or TEDELPARIN*)<BR/>((((((ARGATROBAN or TINZAPARIN) or PARNAPARIN) or REVIPARIN) or DANAPAROID) or LOMOPARAN) OR (ORG and 10172))<BR/>(((((MESOGLYCAN or (POLYSACCHARIDE and SULPHATE*)) OR SP54) OR SP-54) OR MD805) OR MD-805)<BR/>(((CY222 or CY-222) or CY216) or CY-216)<BR/>((((((((#11 or #12) or #13) or #14) or #15) or #16) or #17) or #18) or #19)<BR/>(((MAREVAN or FRAGMIN*) or FRAXIPARIN*) or KLEXANE)<BR/>PIPECOLIC-ACIDS*:ME<BR/>VITAMIN K<BR/>VITAMIN-K*:ME<BR/>VITAMIN K ANTAGONIST*<BR/>(VITAMIN next ANTAGONIST*)<BR/>ANTITHROMBINS*:ME<BR/>BLOOD-COAGULATION-FACTORS*:ME<BR/>BLOOD-COAGULATION*:ME<BR/>(ANTICOAGULAT* or ANTITHROMB*)<BR/>(((((((#21 or #22) or #24) or #26) or #27) or #28) or #29) or #30)<BR/>(((#9 or #10) or #20) or #31)<BR/>(PLATELET and AGGREG*)<BR/>PLATELET-AGGREGATION-INHIBITORS*:ME<BR/>(((((ANTIPLATELET* or ANTI-PLATELET*) or ANTIAGGREG*) or ANTI-AGGREG*) OR (PLATELET* near INHIBIT*)) OR (THROMBOCYT* NEAR INHIBIT*))<BR/>(((((ALPROSTADIL* or ASPIRIN*) or DIPYRIDAMOL*) or DISINTEGRIN*) or EPOPROSTENOL*) or ILOPROST*)<BR/>((((KETANSERIN* or (KETOROLAC and TROMETHAMINE*)) OR MILRINONE*) OR MOPIDAMOL*) OR PENTOXIF*)<BR/>(((PROCAINAMIDE or TICLOPIDINE*) or THIOPHEN*) or TRAPIDIL)<BR/>((((ACETYL and (SALICYLIC and ACID*)) or (ACETYLSALICYLIC and ACID)) OR CLOPIDOGREL*) OR PICOTAMIDE)<BR/>((((((LIGUSTRAZINE* or LEVAMISOL*) or SULOCTIDIL*) or OZAGREL*) or OKY046) or OKY-046) or DEFIBROTIDE)<BR/>((((((((CILOSTAZOL or SATIGREL) or SARPOLGRELATE) or KBT3022) or KBT-3022) or ISBOGREL) or CV4151) or CV-4151) or TRIFLUSAL)<BR/>((((((#35 or #36) or #37) or #38) or #39) or #40) or #41)<BR/>((((DISPRIL or ALBYL*) or TICLID*) or PERSANTIN*) or PLAVIX)<BR/>PLATELET-GLYCOPROTEIN-GPIIB-IIIA-COMPLEX*:ME<BR/>(((GLYCOPROTEIN and IIB) or GP-IIB) NEAR (ANTAGONIST* OR INHIBITOR*))<BR/>((((GR144053 or GR-144053) or ABCIXIMAB*) or TIROFIBAN*) or EFTIFIBATID*)<BR/>((REOPRO or INTEGRILIN*) or AGGRASTAT)<BR/>((((#43 or #44) or #45) or #46) or #47)<BR/>PLATELET-ACTIVATION*:ME<BR/>BLOOD-PLATELETS*:ME<BR/>#33 or #34 or #42 or #48 or #49 or #50<BR/>((#8 and #32) and #51)<BR/>SR-STROKE<BR/>(#52 not #53)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-07-16 15:20:33 +0100" MODIFIED_BY="Hazel Fraser" NO="2">
<TITLE MODIFIED="2008-07-16 15:20:22 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-16 15:20:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>The search strategy for MEDLINE is given below. The search strategy was modified for EMBASE.</P>
<P>1. cerebrovascular disorders/<BR/>2. carotid artery diseases/ or carotid artery thrombosis/<BR/>3. exp cerebrovascular accident/<BR/>4. exp hypoxia-ischemia, brain/<BR/>5. intracranial arterial diseases/ or exp cerebral arterial diseases/<BR/>6. exp "Intracranial embolism and thrombosis"/<BR/>7. (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or transient isch?emic attack$ or tia$).tw<BR/>8. (brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation).tw<BR/>9. (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$).tw<BR/>10. 8 and 9<BR/>11. or/1-7, 10<BR/>12. exp Anticoagulants/<BR/>13. anticoagulant$.tw<BR/>14. (acenocoumarol$ or dicoumarol$ or ethyl biscoumacetate$ or phenprocoumon$ or warfarin$ or ancrod$ or citric acid$ or coumarin$ or chromonar$ or coumestro$ or esculi$ or ochratoxin$ or umbelliferone$ or dermatan?sul$ or dextran$ or edetic acid$ or enoxaparin$ or gabexate$ or heparin$ or lmwh$ or nadroparin$ or pentosan sulfuric polyester$ or phenindione$ or protein c or protein s or tedelparin$).tw<BR/>15. (argatroban or tinzaparin or parnaparin or reviparin or danaparoid or lomoparan or org 10172 or mesoglycan or polysaccharide sulphate$ or sp54 or sp-54 or md805 or md-805 or cy222 or cy-222 or cy216 or cy-216).tw<BR/>16. (Marevan or Fragmin$ or Fraxiparin$ or Klexane).tw<BR/>17. exp Pipecolic acids/ae, tu<BR/>18. exp Vitamin K/ai<BR/>19. Vitamin K antagonist$.tw<BR/>20. exp Antithrombins/ae, pd, de, tu<BR/>21. exp Blood coagulation factors/ai, de<BR/>22. exp Blood coagulation/de<BR/>23. (anticoagulat$ or antithromb$).tw<BR/>24. or/12-23<BR/>25. exp Platelet aggregation inhibitors/<BR/>26. (antiplatelet$ or anti-platelet$ or antiaggreg$ or anti-aggreg$ or (platelet$ adj5 inhibit$) or (thrombocyt$ adj5 inhibit$)).tw<BR/>27. (alprostadil$ or aspirin$ or dipyridamol$ or disintegrin$ or epoprostenol$ or iloprost$ or ketanserin$ or ketorolac tromethamine$ or milrinone$ or mopidamol$ or pentoxifyllin$ or procainamide$ or ticlopidine$ or thiophen$ or trapidil$).tw<BR/>28. (acetyl salicylic acid$ or acetyl?salicylic acid or clopidogrel$ or picotamide$ or ligustrazine$ or levamisol$ or suloctidil$ or ozagrel$ or oky046 or oky-046 or defibrotide$ or cilostazol or satigrel or sarpolgrelate or kbt3022 or kbt-3022 or isbogrel or cv4151 or cv-4151 or triflusal).tw<BR/>29. (Dispril or Albyl$ or Ticlid$ or Persantin$ or Plavix).tw<BR/>30. exp Platelet glycoprotein gpiib-iiia complex/ai, de<BR/>31. (((glycoprotein iib$ or gp iib$) adj5 (antagonist$ or inhibitor$)) or GR144053 or GR-144053 or abciximab$ or tirofiban$ or eftifibatid$).tw<BR/>32. (ReoPro or Integrilin$ or Aggrastat).tw<BR/>33. exp Platelet activation/de<BR/>34. exp Blood platelets/de<BR/>35. or/25-34<BR/>36. 11 and 24 and 35<BR/>37. limit 36 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>